Patent Grant
8387612
This disclosure relates to heating units capable of rapid heating and to articles and methods employing such heating units.
Self-contained heat sources are employed in a wide-range of industries, from food industries for heating food and drink, to outdoor recreation industries for providing hand and foot warmers, to medical applications for inhalation devices. Many self-contained heating sources are based on either an exothermic chemical reaction or on ohmic heating. For example, self-heating units that produce heat by an exothermic chemical reaction often have at least two compartments, one for holding a heat-producing composition and one for holding an activating solution. The two compartments are separated by a frangible seal, that when broken allows mixing of the components to initiate an exothermic reaction to generate heat. (see for example U.S. Pat. Nos. 5,628,304; 4,773,389; 6,289,889). This type of non-combustible, self-heating unit is suitable for heating food, drink, or cold toes and fingers, since the heat production is relatively mild.
Another common source for self-contained heat is ohmic heating. In ohmic heating a current is passed through an electrically resistive material to generate heat that is transmitted to an adjacent article. This mode of heat production has been employed to vaporize or heat a volatile substance, for example tobacco, for inhalation by a user. Cigarette holders and pipe bowls having an electrical resistance coil to generate heat in order to volatilize tobacco flavors have been described (U.S. Pat. Nos. 2,104,266; 4,922,901; 6,095,143). Heating of drugs other than tobacco by ohmic heating have also been described. For example, WO 94/09842 to Rosen describes applying a drug to an electrically resistive surface and heating the surface to vaporize the drug for inhalation. Ohmic heating has the advantage of facilitating precise control of the energy applied to determine the heat generated. However, in many ohmic heating systems, and in particular for small systems where limited energy is available, such as, for example, when using batteries, there can be a substantial delay on the order of seconds or minutes between the time heating is initiated and maximum temperature is achieved. Moreover, for small devices, such as for example, portable medical devices, where the power source comprises a battery, ohmic heating can be expensive and bulky.
Another approach for providing a controlled amount of heat is using electrochemical interactions. Here, components that interact electrochemically after initiation in an exothermic reaction are used to generate heat. Exothermic electrochemical reactions include reactions of a metallic agent and an electrolyte, such as a mixture of magnesium granules and iron particles as the metallic agent, and granular potassium chloride crystals as the electrolyte. In the presence of water, heat is generated by the exothermic hydroxylation of magnesium, where the rate of hydroxylation is accelerated in a controlled manner by the electrochemical interaction between magnesium and iron, which is initiated when the potassium chloride electrolyte dissociates upon contact with the liquid water. Electrochemical interactions have been used in the smoking industry to volatilize tobacco for inhalation (U.S. Pat. Nos. 5,285,798; 4,941,483; 5,593,792).
The aforementioned self-heating methods are capable of generating heat sufficient to heat an adjacent article to several hundred degrees Celsius in a period of several minutes. There remains a need in the art for a device capable of rapid heat production, i.e., on the order of seconds and fractions of seconds, capable of heating an article to within a defined temperature range, and which is suitable for use in articles to be used by people.
Certain embodiments include a heating unit comprising an enclosure comprising a substrate having an exterior surface and an interior surface, wherein the substrate has a thickness in the range of 0.001 to 0.020 inches; a layer of solid fuel covering an area of the interior surface of the substrate corresponding to an area of the exterior surface of the substrate to be heated, wherein the solid fuel layer has a thickness in the range of 0.001 to 0.030 inches and wherein the solid fuel is configured to heat a portion of the exterior surface of the at least one substrate to a temperature of at least 200° C. within 1 second follow ignition of the solid fuel; and an igniter disposed at least partially within the enclosure for igniting the solid fuel. In certain embodiments, within 1 second after ignition of the solid fuel, no more than 10% of said area of the exterior surface has a temperature 50° C. to 100° C. less than the remaining 90% of said area of the exterior surface. Additionally, in certain embodiments, within 500 milliseconds after ignition of the solid fuel, no more than 10% of said area of the exterior surface has a temperature 50° C. to 100° C. less than the remaining 90% of said area of the exterior surface. In certain embodiments, within 250 milliseconds after ignition of the solid fuel, no more than 10% of said area of the exterior surface has a temperature 50° C. to 100° C. less than the remaining 90% of said area of the exterior surface. In certain embodiments, the thin layer of solid fuel has a thickness in the range of 0.001 to 0.005 inches. In certain embodiments, the enclosure comprises more than one substrate. In certain embodiments, the substrate is a metal foil having a thickness in the range of 0.001 to 0.010 inches.
Certain embodiments include a heating unit, wherein the solid fuel comprises a metal reducing agent and a metal containing oxidizing agent. In certain embodiments, the metal containing oxidizing agent is selected from at least one of the following: MoO3, KClO4, KClO3, and Fe2O3. In certain embodiments, the metal reducing agent is selected from at least one of the following: aluminum, zirconium, iron, and titanium. In certain embodiments, the amount of metal reducing agent comprises from 60% to 90% by weight of the total dry weight of the solid fuel. In certain embodiments, the amount of metal reducing agent comprises from 10% to 40% by weight of the total dry weight of the solid fuel.
Certain embodiments include a heating unit, wherein the solid fuel comprises at least one additive material. In certain embodiments, the additive material is selected from at least one of the following: a clay gelling agent, nitrocellulose, polyvinylalcohol, diatomaceous earthy glass beads and a colloidal silica.
Certain embodiments include a heating unit, wherein the substrate has a thickness in the range of 0.002 to 0.010 inches. In certain embodiments, the substrate has a thickness in the range of 0.002 to 0.005 inches.
Certain embodiments include a heating unit, wherein the substrate is a metal, an alloy, or a ceramic.
Certain embodiments include a heating unit, wherein the igniter comprises: an optical window in the enclosure; and a light sensitive initiator composition disposed within the enclosure. In certain embodiments, the initiator composition comprises a reducing agent and an oxidizing agent. In certain embodiments, the reducing agent of the initiator composition is selected from at least one of the following: zirconium, titanium, and aluminum. In certain embodiments, the oxidizing agent of the initiator composition is selected from at least one of the following: molybdenum trioxide, potassium perchlorate, copper oxide, and tungsten trioxide. In certain embodiments, the initiator composition comprises aluminum, boron, molybdenum trioxide, and a clay gelling agent.
Certain embodiments include a heating unit, wherein the substrate comprises a multi-layer structure. In certain embodiments, substrate is a polyimide, a polyester, or a fluoropolymer.
Certain embodiments include a heating unit, wherein the igniter is a percussive igniter. In certain embodiments, at least one impulse absorbing material is disposed within the enclosure. In certain embodiments, a spacer provides an empty volume within the enclosure.
Certain embodiments include a heating unit, wherein at the least one substrate is a metal, an alloy, or a ceramic.
Certain embodiments include a heating unit, wherein the enclosure is capable of withstanding an internal pressure of at least 50 psig.
Certain embodiments include a heating unit, wherein a drug layer is on a portion of the exterior surface of the at least one substrate.
Certain embodiments disclose methods of controlling uniformity of temperature and peak temperature of a substrate surface by coating a thin layer of a selected mass of a solid fuel on a surface of the substrate.
Certain embodiments include heating units comprising an enclosure and a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction disposed within the enclosure. The solid fuel in these heating units can be actuated using a variety of ignition systems.
Certain embodiments include drug supply units comprising an enclosure having at least one substrate having an exterior surface and an interior surface, a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction disposed within the enclosure, and a drug disposed on a portion of the exterior surface of the substrate.
Certain embodiments include drug delivery devices comprising a housing defining an airway, a heating unit comprising an enclosure having at least one substrate having an exterior surface and an interior surface, and a solid fuel capable of undergoing an exothermic metal oxidation-reduction reaction disposed within the enclosure, a drug disposed on a portion of the exterior surface of the substrate, wherein the portion of the exterior surface comprising the drug is configured to be disposed within the airway, and an igniter configured to ignite the solid fuel.
Certain embodiments include methods of producing an aerosol of a drug and of treating a disease in a patient using such heating units, drug supply units, and drug delivery devices.
It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of certain embodiments, as claimed.
Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.”
In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including,” as well as other forms, such as “includes” and “included,” is not limiting. Also, terms such as “element” or “component” encompass both elements and components comprising one unit and elements and components that comprise more than one subunit unless specifically stated otherwise.
Heating Unit
An embodiment of a heating unit is shown in
In certain embodiments, heating unit 10 can comprise an expanse of a solid fuel 20. Solid fuel 20 can be adjacent to the interior surface 14, where the term “adjacent” refers to indirect contact as distinguished from “adjoining” which herein refers to direct contact. As shown in
The components of the solid fuel can react in an exothermic reaction to produce heat. For example, the solid fuel can react in an exothermic oxidation-reduction reaction or an intermetallic alloying reaction. An oxidation-reduction reaction refers to a chemical reaction in which one compound gains electrons and another compound loses electrons. The compound that gains electrons is referred to as an oxidizing agent, and the compound that loses electrons is referred to as a reducing agent. An example of an oxidation-reduction reaction is a chemical reaction of a compound with molecular oxygen (O2) or an oxygen-containing compound that adds one or more oxygen atoms to the compound being oxidized. During the oxidation-reduction reaction, the molecular oxygen or the oxygen-containing compound is reduced by the compound being oxidized. The compound providing oxygen acts as the oxidizer or oxidizing agent. The compound being oxidized acts as the reducing agent. Oxidation-reduction reactions can be exothermic, meaning that the reactions generate heat. An example of an exothermic oxidation-reduction reaction is the thermite reaction of a metal with a metal oxidizing agent. In certain embodiments, a solid fuel can comprise a metal reducing agent and an oxidizing agent, such as for example, a metal-containing oxidizing agent.
In certain embodiments, a metal reducing agent can include, but is not limited to molybdenum, magnesium, calcium, strontium, barium, boron, titanium, zirconium, vanadium, niobium, tantalum, chromium, tungsten, manganese, iron, cobalt, nickel, copper, zinc, cadmium, tin, antimony, bismuth, aluminum, and silicon. In certain embodiments, a metal reducing agent can include aluminum, zirconium, and titanium. In certain embodiments, a metal reducing agent can comprise more than one metal reducing agent.
In certain embodiments, an oxidizing agent can comprise oxygen, an oxygen based gas, and/or a solid oxidizing agent. In certain embodiments, an oxidizing agent can comprise a metal-containing oxidizing agent. In certain embodiments, a metal-containing oxidizing agent includes, but is not limited to, perchlorates and transition metal oxides. Perchlorates can include perchlorates of alkali metals or alkaline earth metals, such as, but not limited to, potassium perchlorate (KClO4), potassium chlorate (KClO3), lithium perchlorate (LiClO4), sodium perchlorate (NaClO4), and magnesium perchlorate [Mg(ClO4)2]. In certain embodiments, transition metal oxides that function as oxidizing agents include, but are not limited to, oxides of molybdenum, such as MoO3, iron, such as Fe2O3, vanadium (V2O5), chromium (CrO3, Cr2O3), manganese (MnO2), cobalt (Co3O4), silver (Ag2O), copper (CuO), tungsten (WO3), magnesium (MgO), and niobium (Nb2O5). In certain embodiments, the metal-containing oxidizing agent can include more than one metal-containing oxidizing agent.
In certain embodiments, the metal reducing agent forming the solid fuel can be selected from zirconium and aluminum, and the metal-containing oxidizing agent can be selected from MoO3 and Fe2O3.
The ratio of metal reducing agent to metal-containing oxidizing agent can be selected to determine the ignition temperature and the burn characteristics of the solid fuel. An exemplary chemical fuel can comprise 75% zirconium and 25% MoO3, percentage based on weight. In certain embodiments, the amount of metal reducing agent can range from 60% by weight to 90% by weight of the total dry weight of the solid fuel. In certain embodiments, the amount of metal-containing oxidizing agent can range from 10% by weight to 40% by weight of the total dry weight of the solid fuel. In certain embodiments, the amount of oxidizing agent in the solid fuel can be related to the molar amount of the oxidizers at or near the eutectic point for the fuel composition. In certain embodiments, the oxidizing agent can be the major component and in others the metal reducing agent can be the major component. Those of skill in the art are able to determine the appropriate amount of each component based on the stoichiometry of the chemical reaction and/or by routine experimentation. Also as known in the art, the particle size of the metal and the metal-containing oxidizer can be varied to determine the burn rate, with smaller particle sizes selected for a faster burn (see, for example, U.S. Pat. No. 5,603,350).
In certain embodiments, a solid fuel can comprise additive materials to facilitate, for example, processing and/or to determine the thermal and temporal characteristics of a heating unit during and following ignition of the solid fuel. An additive material can be reactive or inert. An inert additive material will not react or will react to a minimal extent during ignition and burning of the solid fuel. The additive can comprise inorganic or organic materials. In certain applications, particularly, where it is desirous to produce a minimal amount of gas, such as for example, in a sealed heating unit, the additive material can be inorganic materials and can function as binders, adhesives, gelling agents, thixotropic agents, and/or surfactants. Examples of gelling agents include, but are not limited to, clays such as LAPONITE®, Montmorillonite, CLOISITE®, metal alkoxides, such as those represented by the formula R—Si(OR)n and M(OR)n where n can be 3 or 4, and M can be Ti, Zr, Al, B or other metals, and collidal particles based on transition metal hydroxides or oxides. Examples of binding agents include, but are not limited to, soluble silicates such as Na— or K-silicates, aluminum silicates, metal alkoxides, inorganic polyanions, inorganic polycations, and inorganic sol-gel materials, such as alumina or silica-based sols.
In certain embodiments, the solid fuel comprises LAPONITE®, and in particular LAPONITE® RDS, as an inert additive material. LAPONITE® is a synthetic layered silicate, and in particular a magnesium phyllosilicate, with a structure resembling that of the natural clay mineral hectorite (Na0.4Mg2.7Li0.3Si4O10(OH)2). LAPONITE® RD is a commercial grade material which, when added to water, rapidly disperses to form a gel when hydrated (Southern Clay Products, Gonzales, Tex.). LAPONITE® RD has the following chemical analysis in weight percent: 59.5% SiO2:27.5% MgO:0.8% Li2O: 2.8% Na2O. LAPONITE® RDS (Southern Clay Products, Gonzales, Tex.) is a commercially available sol-forming grade of LAPONITE® modified with a polyphosphate dispersing agent, or peptizer, to delay rheological activity until the LAPONITE® RDS is added as a dispersion into a formulation. A sol refers to a colloid having a continuous liquid phase in which solid is suspended in a liquid. LAPONITE® RDS has the following chemical analysis in weight percent: 54.5% SiO2:26% MgO:0.8% Li2O:5.6% Na2O:4.1% P2O5. In the presence of electrolytes, LAPONITEs® can act as gelling and thixotropic agents. Thixotropy refers to the property of a material to exhibit decreased viscosity under shear.
When incorporated into a solid fuel composition comprising a metal reducing agent and a metal-containing oxidizing agent, such as any of those disclosed herein, in addition to imparting gelling and thixotropic properties, LAPONITE® RDS can also act as binder. A binder refers to an additive that produces bonding strength in a final product. The binder can impart bonding strength, for example, by forming a bridge, film, matrix, and/or chemically self-react and/or react with other constituents of the formulation.
In certain embodiments, for example, when the solid fuel is disposed on a substrate as a film or thin layer, wherein the thickness of the thin layer of solid fuel can range, for example, from 0.001 inches to 0.030 inches, it can be useful that the solid fuel adhere to the surface of the substrate and that the constituents of the solid fuel adhere to each other, and maintain physical integrity. In certain embodiments, it can be useful that the solid fuel remain adhered to the substrate surface and maintain physical integrity during processing, storage, and use during which time the solid fuel coating can be exposed to a variety of mechanical and environmental conditions. Several additives, such as those disclosed herein, can be incorporated into the solid fuel to impart adhesion and physical robustness to the solid fuel coating.
In certain embodiments, small amounts of LAPONITE® RDS added to a solid fuel slurry comprising a metal reducing agent and a metal-containing oxidizing agent can impart thixotropic, gelling and in particular, adhesive properties to the solid fuel.
An example of the preparation of a solid fuel comprising LAPONITE® RDS and the application of the solid fuel to a metal foil substrate are described in Example 1.
Other useful additive materials include glass beads, diatomaceous earth, nitrocellulose, polyvinylalcohol, and other polymers that may function as binders. In certain embodiments, the solid fuel can comprise more than one additive material. The components of the solid fuel comprising the metal, oxidizing agent and/or additive material and/or any appropriate aqueous- or organic-soluble binder, can be mixed by any appropriate physical or mechanical method to achieve a useful level of dispersion and/or homogeneity. In certain embodiments, the solid fuel can be degassed.
In addition to the enhanced binding properties of the solid fuels with additive, other advantages of using inorganic additives include stability of the additive up to very high temperatures and lack of, or minimal release of, any toxic gases by the additive. In an enclosed system, this lack of additional gas production from the inorganic additive also reduces or minimizes the possibility of rupture of the enclosed heating unit.
Tables 1A-1E summarize certain embodiments of solid fuel compositions including the additives used. The weight ratio of the components comprising certain solid fuel compositions are provided.
While the use of additives in the solid fuel can improve the binding properties of the solid fuel, it also can improve the ease of use and manufacturability of substrates coated with such fuel. In particular, use of additives can make it possible to use wet-coating techniques, such as, for example, but not limitation, dip coating, spray coating, roller coating, gravure coating, reverse roll coating, gap coating, metering rod coating, slot die coating, curtain coating, and air knife coating, as means for deposition of a fuel powder on a substrate surface, such as, for example, either inside, or on, a cylindrical type surface such as the internal surface of the substrate in
The use of solid fuel slurries with additives for coating a substrate can provide for better mixing of the materials, enhanced adherence properties, and more control over the even disbursement of the solid fuel on a surface. While preparing a physical mixture of solid fuel powders as an essentially homogeneous layer around the walls of a cylindrical device can be done, it is problematic, especially if the materials used have differences in densities, particle sizes, shapes, surface volume ratios, and lack chemically attractive surface-surface interactions. (Essentially homogeneous is defined, for purposes herein, as essentially uniform; and when applied to a mixture of two or more components, it refers to a basically uniform distribution of the various different particles throughout the mixture. This is in contrast to a heterogeneous mixture of components where various components tend to aggregate and there is settling out of the higher density particles.) Use of a core for dispersing mixtures of fuel powders to an interior surface of a substrate, allows one to control the gap or layer thickness of the solid fuel layer; however, it does not prevent other problems such as segregation of the particles in the mixture. Inadequate homogeneity as to the fuel mixture itself, due to ineffective mixing can result in inconsistent heating of the exterior surface of the substrate. Mixing can be facilitated and even automated when done as a slurry as opposed to a dry powder.
Additionally, lack of homogeneity as to the fuel thickness on, or in, contact with an interior surface of a substrate can also result in inconsistent heating of the exterior surface of a substrate. Coating adherence and ease of application can be enhanced by the use of slurries with additives.
In certain embodiments, the solid fuel is disposed on a substrate as a coating or thin layer, wherein the thickness of the thin layer of solid fuel can range, for example, from 0.001 inches to 0.030 inches by use of wet coating
Substrates such as, for example, substrates 510 shown in
In certain embodiments, the metal reducing agent and the oxidizing agent can be in the form of a powder. The term “powder” refers to powders, particles, prills, flakes, and any other particulate that exhibits an appropriate size and/or surface area to sustain self-propagating ignition. For example, in certain embodiments, the powder can comprise particles exhibiting an average diameter ranging from 0.1 μm to 200 μm.
In certain embodiments, a solid fuel can comprise a multilayer comprising reactants capable of undergoing a self-sustaining exothermic reaction. A multilayer solid fuel comprising alternating and/or interposed layers of materials capable of reacting exothermically, can be continuous, or can be discontinuous. Each of the multiple layers can be homogeneous or heterogeneous. A discontinuous layer refers to a layer that can be patterned and/or have openings. The use of discontinuous layers can increase the contact to the reactions; and by bringing the reactants into proximity, can thereby facilitate the exothermic reaction. Each layer can comprise one or more reactants, and can comprise one or more additive materials such as binders, gelling agents, thixotropic agents, adhesives, surfactants, and the like.
The reacting layers can be formed into a multilayer structure by any appropriate method that at least in part can be determined by the chemical nature of the reactants in a particular layer. In certain embodiments, metal foils or sheets of two or more reactants can be cold pressed/rolled to form a multilayer solid fuel. Multilayer solid fuels can comprise alternating or mixed layers of reactants and can be formed by vapor deposition, sputtering or electrodeposition methods. Using wet coating methods, multiple layers of dispersions comprising the reactants can be deposited to form a multilayer solid fuel, wherein each layer can comprise the same or different composition.
The number of layers and the thickness of each layer of reactants can be selected to establish the thermal and temporal characteristics of the exothermic reaction. Depending in part on the method used to form the multilayer solid fuel, the thickness of a layer can range from, for example, 0.1 μm to 200 μm for a metal sheet, and can range from, for example, 1 nm to 100 μm for a vapor- or electro-deposited layer. The reactant layers can comprise elemental metals, alloys and/or metal oxides. Examples of layer pairs can include, but are not limited to Al:Ni, Al:Cu, Ti:Ni, Ti:C, Zr:B, Mo:Si, Ti:Si, and Zr:S. These and other combinations of reactants and/or additive materials can be used to control the burning characteristics of the solid fuel.
In certain embodiments, the multilayer structure can be repeatedly mechanically deformed to intermix the reactant layers. In certain embodiments, such as where layers are deposited by, for example, vapor deposition, sputtering or electrodeposition methods, the reactants can be deposited to form an intermixed or heterogeneous composition.
In addition to the layers comprising reactants, a multilayer solid fuel structure can comprise layers of non-reacting materials or materials having certain reaction properties to facilitate control of the thermal and temporal characteristics of the exothermic reaction.
In certain embodiments, a solid fuel can be machined, molded, pre-formed or packed. The solid fuel can be formed as a separate element configured to be inserted into a heating unit, or the solid fuel can be applied directly to a heating unit. In certain embodiments, a solid fuel can be coated, applied, or deposited directly onto a substrate forming part of a heating unit, onto a support that can be incorporated into a heating unit, or onto a support configured to transfer the solid fuel to a substrate forming a heating unit.
The solid fuel can be any appropriate shape and have any appropriate dimensions. For example, as shown in
In the various embodiments, fuel can be ignited to generate a self-sustaining oxidation-reduction reaction. Once a portion of the solid fuel is ignited, the heat generated by the oxidation-reduction reaction can ignite adjacent unburned fuel until all of the fuel is consumed in the process of the chemical reaction. The exothermic oxidation-reduction reaction can be initiated by the application of energy to at least a portion of the solid fuel. Energy absorbed by the solid fuel or by an element in contact with the solid fuel can be converted to heat. When the solid fuel becomes heated to a temperature above the auto-ignition temperature of the reactants, e.g. the minimum temperature required to initiate or cause self-sustaining combustion in the absence of a combustion source or flame, the oxidation-reduction reaction will initiate, igniting the solid fuel in a self-sustaining reaction until the fuel is consumed.
Energy can be applied to ignite the solid fuel using a number of methods. For example, a resistive heating element can be positioned in thermal contact with the solid fuel, which when a current is applied, can heat the solid fuel to the auto-ignition temperature. An electromagnetic radiation source can be directed at the solid fuel, which when absorbed, can heat the solid fuel to its auto-ignition temperature. An electromagnetic source can include lasers, diodes, flashlamps and microwave sources. RF or induction heating can heat the solid fuel source by applying an alternating RF field that can be absorbed by materials having high magnetic permeability, either within the solid fuel, or in thermal contact with the solid fuel. The source of energy can be focused onto the absorbing material to increase the energy density to produce a higher local temperature and thereby facilitate ignition. In certain embodiments, the solid fuel can be ignited by percussive forces.
The auto-ignition temperature of a solid fuel comprising a metal reducing agent and a metal-containing oxidizing agent as disclosed herein can range of 400° C. to 500° C. While such high auto-ignition temperatures facilitate safe processing and safe use of the solid fuel under many use conditions, for example, as a portable medical device, for the same reasons, to achieve such high temperatures, a large amount of energy must be applied to the solid fuel to initiate the self-sustaining reaction. Furthermore, the thermal mass represented by the solid fuel can require that an impractically high temperature be applied to raise the temperature of the solid fuel above the auto-ignition temperature. As heat is being applied to the solid fuel and/or a support on which the solid fuel is disposed, heat is also being conducted away. Directly heating a solid fuel can require a substantial amount of power due to the thermal mass of the solid fuel and support.
As is well known in the art, for example, in the pyrotechnic industry, sparks can be used to safely and efficiently ignite fuel compositions. Sparks refer to an electrical breakdown of a dielectric medium or the ejection of burning particles. In the first sense, an electrical breakdown can be produced, for example, between separated electrodes to which a voltage is applied. Sparks can also be produced by ionizing compounds in an intense laser radiation field. Examples of burning particles include those produced by friction and break sparks produced by intermittent electrical current. Sparks of sufficient energy incident on a solid fuel can initiate the self-sustaining oxidation-reduction reaction.
When sufficiently heated, the exothermic oxidation-reduction reaction of the solid fuel can produce sparks, as well as radiation energy. Thus, in certain embodiments, reliable, reproducible and controlled ignition of the solid fuel can be facilitated by the use of an initiator composition capable of reacting in an exothermic oxidation-reduction reaction. The initiator composition can comprise the same or similar reactants as those comprising the solid fuel. In certain embodiments, the initiator composition can be formulated to maximize the production of sparks having sufficient energy to ignite a solid fuel. Sparks ejected from an initiator composition can impinge upon the surface of the solid fuel, causing the solid fuel to ignite in a self-sustaining exothermic oxidation-reduction reaction. The igniter can comprise a physically small, thermally isolated heating element on which is applied a small amount of an initiator composition capable of producing sparks or the initiator composition can be placed directly on the fuel itself and ignited by a variety of means, including, for example, optical or percussive.
As shown in
Initiator compositions capable of producing sparks upon exposure to heat, force, or a spark are known, for example, in the pyrotechnic field and the photoflash industry. In certain embodiments, an initiator composition can comprise at least one metal, such as those described herein, and at least one oxidizing agent, such as, for example, a chlorate or perchlorate of an alkali metal or an alkaline earth metal or metal oxide and others disclosed herein. In certain embodiments, an initiator composition can include at least one binder and/or additive material such as a gelling agent and/or binder. Examples of additive materials including gelling agents and/or binders are disclosed herein. In certain embodiments, additive materials can be useful in determining certain processing, ignition, and/or burn characteristics of the initiator composition.
In certain embodiments, solid fuel 80 comprising, for example, any of the solid fuels described herein, can be confined between substrate 62 and backing member 74 or can fill inner region 72. Solid fuel 80 can adjoin interior surface 68 of substrate 62.
In certain embodiments, initiator composition 82 can be positioned in open receptacle 66 of substrate 62, and can be configured to ignite solid fuel 80. In certain embodiments, a retaining member 84 can be located in open receptacle 66 and can be secured in place using any suitable mechanism, such as for example, bonding or welding. Retaining member 84 and substrate 62 can be sealed to prevent release of the reactants or reaction products produced during ignition and burn of initiator composition 82 and solid fuel 80. Retaining member 84 can include a recess 86 in the surface facing inner region 72. Recess 86 can retain initiator composition 82. In certain embodiments, an electrical stimulus can be applied directly to initiator composition 82 via leads 88, 90 connected to the positive and negative termini of a power source, such as a battery (not shown). Leads 88, 90 can be connected to an electrically resistive heating element placed in physical contact with the initiator composition 82 (not shown). In certain embodiments, leads 88, 90 can be coated with the initiator composition 82.
Referring to
An embodiment of a heating unit is illustrated in
In certain embodiments, the igniter can comprise a support and an initiator composition disposed on the support. In certain embodiments, the support can be thermally isolated to minimize the potential for heat loss. In this way, dissipation of energy applied to the combination of assembly and support can be minimized, thereby reducing the power requirements of the energy source, and facilitating the use of physically smaller and less expensive heat sources. In certain applications, for example, with battery powered portable medical devices, such considerations can be particularly useful. In certain embodiments, it can be useful that the energy source be a small low cost battery, such as a 1.5 V alkaline battery. In certain embodiments, the initiator composition can comprise a metal reducing agent and metal-containing oxidizing agent.
In certain embodiments, a metal reducing agent can include, but is not limited to molybdenum, magnesium, calcium, strontium, barium, boron, titanium, zirconium, vanadium, niobium, tantalum, chromium, tungsten, manganese, iron, cobalt, nickel, copper, zinc, cadmium, tin, antimony, bismuth, aluminum, and silicon. In certain embodiments, a metal reducing agent can include aluminum, zirconium, and titanium. In certain embodiments, a metal reducing agent can comprise more than one metal reducing agent. In certain embodiments, an oxidizing agent can comprise oxygen, an oxygen based gas, and/or a solid oxidizing agent. In certain embodiments, an oxidizing agent can comprise a metal-containing oxidizing agent. In certain embodiments, a metal-containing oxidizing agent includes, but is not limited to, perchlorates and transition metal oxides. Perchlorates can include perchlorates of alkali metals or alkaline earth metals, such as but not limited to, potassium perchlorate (KClO4), potassium chlorate (KClO3), lithium perchlorate (LiClO4), sodium perchlorate (NaClO4), and magnesium perchlorate [Mg(ClO4)2]. In certain embodiments, transition metal oxides that function as oxidizing agents include, but are not limited to, oxides of molybdenum, such as MoO3, iron, such as Fe2O3, vanadium (V2O5), chromium (CrO3, Cr2O3), manganese (MnO2), cobalt (Co3O4), silver (Ag2O), copper (CuO), tungsten (WO3), magnesium (MgO), and niobium (Nb2O5). In certain embodiments, the metal-containing oxidizing agent can include more than one metal-containing oxidizing agent.
The ratio of metal reducing agent to metal-containing oxidizing agent can be selected to determine the appropriate burn and spark generating characteristics. In certain embodiments, the amount of oxidizing agent in the initiator composition can be related to the molar amount of the oxidizers at or near the eutectic point for the fuel composition. In certain embodiments, the oxidizing agent can be the major component and in others the metal reducing agent can be the major component. Those of skill in the art are able to determine the appropriate amount of each component based on the stoichiometry of the chemical reaction and/or by routine experimentation. Also as known in the art, the particle size of the metal and the metal-containing oxidizer can be varied to determine the burn rate, with smaller particle sizes selected for a faster burn (see, for example, PCT WO 2004/01396).
In certain embodiments, an initiator composition can comprise additive materials to facilitate, for example, processing, enhance the mechanical integrity and/or determine the burn and spark generating characteristics. The additive materials can be inorganic materials and can function as binders, adhesives, gelling agents, thixotropic, and/or surfactants. Examples of gelling agents include, but are not limited to, clays such as LAPONITE®, Montmorillonite, CLOISITE®, metal alkoxides such as those represented by the formula R—Si(OR)n and M(OR)n where n can be 3 or 4, and M can be Ti, Zr, Al, B or other metals, and colloidal particles based on transition metal hydroxides or oxides. Examples of binding agents include, but are not limited to, soluble silicates such as Na— or K-silicates, aluminum silicates, metal alkoxides, inorganic polyanions, inorganic polycations, inorganic sol-gel materials such as alumina or silica-based sols. Other useful additive materials include glass beads, diatomaceous earth, nitrocellulose, polyvinylalcohol, guor gum, ethyl cellulose, cellulose acetate, polyvinyl-pyrrolidone, fluorocarbon rubber (VITON®) and other polymers that can function as a binder. In certain embodiments, the initiator composition can comprise more than one additive material. The components of the initiator composition comprising the metal, metal-containing oxidizing agent and/or additive material and/or any appropriate aqueous- or organic-soluble binder, can be mixed by any appropriate physical or mechanical method to achieve a useful level of dispersion and/or homogeneity. In certain embodiments, additive materials can be useful in determining certain processing, ignition, and/or burn characteristics of the initiator composition. In certain embodiments, the particle size of the components of the initiator can be selected to tailor the ignition and burn rate characteristics as is known in the art (see for example U.S. Pat. No. 5,739,460 the disclosure of which is hereby incorporated by reference in its entirety).
In certain embodiments, an initiator composition can comprise at least one metal, such as those described herein, and at least one oxidizing agent, such as, for example, a chlorate or perchlorate of an alkali metal or an alkaline earth metal or metal oxide and others disclosed herein.
Examples of initiator compositions include compositions comprising 10% Zr:22.5% B:67.5% KClO3; 49.)% Zr:49.0% MoO3 and 2.0% nitrocellulose, and 33.9% Al:55.4% MoO3:8.9% B:1.8 nitrocellulose; 26.5% Al:51.5% MoO3:7.8% B:14.2% VITON®, in weight percent.
Other initiator compositions can be used. For example, an initiator composition that can ignite upon application of a percussive force comprises a mixture of sodium chlorate (NaClO3), phosphorous (P), and magnesium oxide (MgO).
Energy sufficient to heat the initiator composition to the auto-ignition temperature can be applied to the initiator composition and/or the support on which the initiator composition is disposed. The energy source can be any of those disclosed herein, such as resistive heating, radiation heating, inductive heating, optical heating, and percussive heating. In embodiments wherein the initiator composition is capable of absorbing the incident energy, the support can comprise a thermally insulating material. In certain embodiments, the incident energy can be applied to a thermally conductive support that can heat the initiator composition above the auto-ignition temperature by thermal conduction.
In certain embodiments, the energy source can be an electrically resistive heating element. The electrically resistive heating element can comprise any material that can maintain integrity at the auto-ignition temperature of the initiator composition. In certain embodiments, the heating element can comprise an elemental metal such as tungsten, an alloy such as Nichrome, or other material such as carbon. Materials suitable for resistive heating elements are known in the art. The resistive heating element can have any appropriate form. For example, the resistive heating element can be in the form of a wire, filament, ribbon or foil. In certain embodiments, the electrical resistance of the heating unit can range from 2Ω to 4Ω. The appropriate resistivity of the heating element can at least in part be determined by the current of the power source, the desired auto ignition temperature, or the desired ignition time. In certain embodiments, the auto-ignition temperature of the initiator composition can range from 200° C. to 500° C. The resistive heating element can be electrically connected, and suspended between two electrodes electrically connected to a power source.
The support can comprise one or more heating units.
An embodiment of an igniter comprising a resistive heating element is illustrated in
As shown in
The following procedure was used to apply the initiator composition to resistive heating elements.
A 0.0008 inch diameter Nichrome wire was soldered to Cu conductors disposed on a 0.005 inch thick FR4 epoxy/fiberglass printed circuit board (Onanon). The dimensions of the igniter printed circuit board were 1.82 inches by 0.25 inches. Conductor leads can extend from the printed circuit board for connection to a power source. In certain embodiments, the electrical leads can be connected to an electrical connector.
The igniter printed circuit board was cleaned by sonicating (Branson 8510R-MT) in DI water for 10 minutes, dried, sprayed with acetone and air dried.
The initiator composition comprised 0.68 grams nano-aluminum (40-70 nm diameter; Argonide Nanomaterial Technologies, Sanford, Fla.), 1.23 grams of nano-MoO3 (EM-NTO-U2; Climax Molybdenum, Henderson, Colo.), and 0.2 grams of nano-boron (33,2445-25G; Aldrich). A slurry comprising the initiator composition was prepared by adding 8.6 mL of 4.25% VITON® A500 (4.25 grams VITON® in 100 mL amyl acetate (Mallinckrodt)) solution.
A 1.1 uL drop of slurry was deposited on the heating element, dried for 20 minutes, and another 0.8 uL drop of slurry comprising the initiator composition was deposited on the opposite side of the heating element.
Application of 3.0 V through a 1,000 μF capacitor from two A76 alkaline batteries to the Nichrome heating element ignited the Al:MoO3:B initiator composition within 1 to 50 msec, typically within 1 to 6 msec. When positioned within 0.12″ inches of the surface of a solid fuel comprising a metal reducing agent and a metal-containing oxidizing agent such as, for example, a fuel comprising 76.16% Zr:19.04% MoO3:4.8% LAPONITE® RDS, the sparks produced by the initiator composition ignited the solid fuel to produce a self-sustaining exothermic reaction. In certain embodiments, a 1 μL drop of the slurry comprising the initiator composition can be deposited onto the surface of the solid fuel adjacent the initiator composition disposed on the resistive heating element to facilitate ignition of the solid fuel.
The initiator composition comprising Al:MoO3:B adhered to the Nichrome wire and maintained physical integrity following mechanical and environmental testing including temperature cycling (−25° C.40° C.), drop testing, and impact testing.
In certain embodiments, as shown in
In certain embodiments, the heating units described and illustrated in
A heating unit substantially as illustrated in
Upon ignition of the solid fuel, an exothermic oxidation-reduction reaction produces a considerable amount of energy in a short time, such as for example, in certain embodiments less than 1 second, in certain embodiments less than 500 milliseconds, and in certain embodiments less than 250 milliseconds. Examples of exothermic reactions include electrochemical reactions and metal oxidation-reduction reactions. When used in enclosed heating units, by minimizing the quantity of reactants and the reaction conditions the reaction can be controlled but can result in a slow release of heat and/or a modest temperature rise. However, in certain applications, it can be useful to rapidly heat a substrate to temperatures in excess of 200° C. within 1 second or less. Such rapid intense thermal pulses can be useful for vaporizing pharmaceutical compositions to produce aerosols. A rapid intense thermal pulse can be produced using an exothermic oxidation-reduction reaction and in particular a thermite reaction involving a metal and a metal-containing oxidizing agent. Concomitant with the rapid generation of heat, there can be a rapid generation of gaseous products and unreacted reactants with high translational energies. When sealed within an enclosure, the exothermic oxidation-reduction reaction can generate a significant increase in pressure.
Energy produced by the exothermic reaction, whether thermal, optical, mechanical, e.g. particle ejection, or chemical can generate a significant pressure when contained with a sealed enclosure. In certain embodiments, a solid fuel capable of reacting in an exothermic oxidation-reduction reaction can be used to form a heating unit. For example, solid fuel as disclosed herein can be used to thermally vaporize a drug coating to produce an aerosol of a drug for medical applications. In certain applications, such as in portable medical devices, it can be useful to contain the pyrothermic materials and products of the exothermic reaction and other chemical reactions resulting from the high temperatures within the enclosure. While containing the exothermic reaction can be accomplished by adequately sealing the enclosure to withstand the internal pressures resulting from the burning of the solid fuel as well as an initiator composition if present, it can be useful to minimize the internal pressure to ensure the safety of the heating device and facilitate device fabrication.
In certain embodiments, the pressure within the substrate can increase during and after ignition and burning of the initiator composition and the solid fuel. The increase in pressure can depend, at least in part, on the amount and composition of the solid fuel, the relative amounts of the fuel components, the density and/or degree of compaction of the solid fuel, the particle size of the fuel components, the configuration of the substrate, the amount of initiator, and/or the composition of the initiator. In certain embodiments, a solid fuel, an initiator composition, and a substrate configuration can be selected to control the pressure increase and maintain the maximum pressure within a useful operating range. The initiator composition and solid fuel can produce gas phase reaction products during ignition and burn. Thus, in certain embodiments, the pressure within the substrate can be managed by minimizing the amount of initiator composition and solid fuel disposed within the heating unit. One of skill can experimentally determine the minimum amount of initiator composition needed to reliably ignite the solid fuel. One of skill can also determine the properties, configuration, and placement of the solid fuel within a heating unit to achieve a useful substrate temperature.
In certain embodiments, the internal pressure of a heating unit can be managed or reduced by constructing the substrate, backing, and any other internal components from materials that produce minimal gas products at elevated temperatures. In certain embodiments, pressure can be managed or reduced by providing an interior volume wherein gas can be collected and/or vented when the initiator and solid fuel are burned. In certain embodiments, the interior volume can include a porous or fibrous material having a high surface area and a large interstitial volume. The interstitial volume can contain a gas generated as a result of the initiator and solid fuel reactions and can thereby reduce the pressure within the enclosure and collisions of the reactants and reaction products with the matrix of the porous or fibrous material can efficiently transfer the internal and translational energy.
The internal pressure of a heating unit during and after burning of an initiator composition and a solid fuel can vary depending on the parameters discussed above. The internal pressure of certain embodiments of heating units was measured using the fixture illustrated in
A heating unit equipped with two pressure transducers, as illustrated in
Measurements of the peak internal pressure within sealed heating units, of a type as shown in
The internal pressure within a heating unit can also be managed or reduced by incorporating materials capable of absorbing, adsorbing or reacting with gas phase reaction products. The surface of the material may intrinsically be capable of absorbing, adsorbing or reacting with the gaseous products, or can be coated or decorated with, for example, elements, compounds and/or compositions. In certain embodiments, the immediate burst of pressure resulting from the solid fuel burn can be reduced by locating an impulse absorbing material and/or coating within the heating unit. An embodiment of a heating unit comprising an impulse absorbing material is schematically illustrated in
In certain embodiments, the impulse absorbing material can comprise a material which can absorb the thermal and translational energy of the reactants and reaction products produced during burning of the solid fuel, and if present, an initiator composition. In certain embodiments, an initiator composition comprising, for example, any of the initiator compositions disclosed herein, can be incorporated into the sealed heating unit to initiate the self-sustaining exothermic reaction of the solid fuel. An impulse absorbing material can present a high surface area to absorb the pressure impulse of thermally and translationally hot molecules and which does not react at the temperatures reached within the heating unit during and following the burn of the solid fuel. Examples of such materials include porous materials such as ceramic membranes, and fibrous materials such as fiber mats. Hot molecules physically and/or thermally ejected from the burning solid fuel can pass through the interstitial spaces defined by porous or fibrous matrix to access a large surface area, which upon collision, can facilitate transfer of thermal and translational energy to the matrix of the impulse absorbing material, thereby reducing the peak pressure within the heating unit.
Examples of porous membranes include, but are not limited to ceramic membranes, fluorocarbon membranes, alumina membranes, polymer membranes, and membranes formed from sintered metal powders. Examples of fibrous materials include, but are not limited to, glass, silica, carbon, graphite, metals, and high temperature resistant polymers. Sponge materials can also be used. The porosity and density of the impulse absorbing material can be selected to reduce the peak pressure by an appropriate amount. For a given amount of solid fuel, composition of solid fuel, and heating unit dimensions, the appropriate porosity and density of the impulse absorbing material can be determined empirically. In certain embodiments, it can be useful to have the pores sufficiently large to facilitate entry of the thermally and translationally hot molecules to the interior of an impulse absorbing material, or to one or more additional layers of impulse absorbing materials with different porosity and/or composition to facilitate transfer of energy from the hot molecules to the impulse absorbing material.
The effect of incorporating glass fiber mats on the internal pressure of a heating unit is shown in
The ability of glass fiber mats to reduce the temperature within a heating unit is shown in
As demonstrated by the results shown in
In certain embodiments, the residual pressure within a heating unit can be reduced by including materials capable of gettering the residual gaseous reaction products. Such materials can be included with the impulse absorbing material, intrinsic to the impulse absorbing material, and/or applied to the impulse absorbing material as a coating, deposit, layer, and the like. In certain embodiments, the getter can be coated or deposited onto a support disposed within a heating unit and/or on one or more interior surfaces of the heating unit.
Getters are materials capable of absorbing, adsorbing and/or reacting with gases and can be used to improve and/or maintain a vacuum, and/or to purify gases. Absorption refers to the process by which one material is retained by another, such as the attachment of molecules of a gas or vapor to a solid surface by physical forces. Adsorption refers to the increase in the concentration of a dissolved substance at the interface of a condensed and a gaseous or liquid phase. Getters are used for example in the semiconductor industry to reduce residual gases in high vacuum systems. In certain embodiments, getters capable of removing hydrogen gas, H2, and molecular oxygen, O2, can include, but are not limited to, compositions including metals and nonmetals, such as Ta, Zr, Tb, Ti, Al, Mg, Ba, Fe, and P. Examples of getters useful for removing H2 gas include, but are not limited to, sintered Zr/graphite powders, Zr/Al compositions, Zr/V/Fe, polymer-bound getters such as PdO/zeolite dispersed in a polymer matrix, and polydiene hydrogenation catalyst compositions. Iron-based and polymeric getters have been developed to absorb O2. Carbon and/or graphite based materials can be used to adsorb and/or absorb H2 and O2. In certain embodiments, a getter can also adsorb, absorb and/or react with volatile intermediate products or the unreacted reactants of the exothermic oxidation-reduction reaction such as, for example, MoOx, CO, CO2, and N2.
A getter can be applied to a substrate by any appropriate method. In certain embodiments, it can be useful to provide a large surface area of getter to rapidly and efficiently reduce the residual gas pressure. This can be accomplished, for example, by providing a getter formed from a porous material, such as a sintered powder, or a fibrous material. In certain embodiments, the getter can be applied to the surface of a porous or fibrous material.
Certain embodiments of heating units were used to examine the burn propagation speed of the solid fuel following ignition. The burn propagation speed refers to the speed of the burn front, which separates unburned and burned solid fuel regions. In certain embodiments, the burn propagation speed can be determined at least in part by the solid fuel composition, the particle size of the components of the solid fuel, the density or level of compaction of the solid fuel, the shape and dimensions of the solid fuel, the material forming the heating unit, and/or any internal components such as a backing member. The temporal and spatial characteristics of the burn propagation speed for cylindrically-shaped heating units were evaluated by monitoring the surface temperature of heating units using an infrared thermal imaging camera (FLIR Systems, Thermacam SC3000).
Thermal images of a cylindrically-shaped heating unit measured by infrared thermal imaging as a function of time, in milliseconds, are shown in
In other studies, heating units as described in Examples 4A and 4B were fabricated and the surface temperature uniformity was evaluated by infrared thermal imaging. Heating units prepared for these studies differed from those used in the investigation of burn propagation speed only in the mass ratio of metal and oxidizing agent used to form the solid fuel. Thermal images taken 400 milliseconds after igniting the solid fuel are shown in
In certain embodiments, it can be useful that at least a portion of the exterior surface of the substrate be heated to a uniform temperature, and that the heated portion be heated at a similar rate. Uniform heating of at least a portion of the substrate can be facilitated by reducing the thermal mass of the substrate in the region to be heated and/or by controlling the amount of solid fuel generating heat. Uniform heating of the exterior surface of the substrate can be useful for vaporizing a compound disposed on the exterior substrate surface in a short period of time to form an aerosol comprising the vaporized compound having high yield and purity. As an example, uniform heating of a 1.3 inch by 1.3 inch substrate area can be achieved by applying a 0.00163+0.000368 inch thick layer of solid fuel onto a 0.004 inch thick foil. Upon ignition, the surface of the foil opposing the surface on which 0.18 g of the solid fuel is applied can reach a maximum temperature of 440° C. over the 1.3 inch by 1.3 inch area at 250 msec after ignition. As will be appreciated by one of skill in the art, the fuel thickness selected will depend on the fuel composition, the foil thickness, and the desired temperature.
Examples 5-7 provide heating units prepared and evaluated for pressure during burn, burn propagation speed, and substrate temperature uniformity. The heating unit described in Example 5 was comprised of a solid fuel composition of Zr, MoO3, KClO3, nitrocellulose, and diatomaceous earth. After remote ignition of the solid fuel from the tip of the heating unit (opening 312 in
The heating unit prepared as described in Example 6 contained a solid fuel composition comprised of Zr, MoO3, and nitrocellulose. The gap or annular shell between the substrate and backing member was 0.020 inches. The external surface of the backing member was coated with initiator composition to increase the burn propagation speed. The solid fuel was remotely ignited from the tip of the heating unit (opening 312 in
The heating unit prepared as described in Example 7 contained a solid fuel composition of Al, MoO3, and nitrocellulose. The solid fuel was placed in a 0.020-inch annular shell gap between the substrate and the backing member. The solid fuel was directly ignited near the plug. The internal pressure increased to 300 psig during the reaction period of less than 5 milliseconds. The residual pressure was under 60 psig. The exterior surface of the substrate was uniformly heated, with between 5 percent to 10 percent of the exterior surface exhibiting a temperature 50° C. to 100° C. less than that of the remaining exterior surface.
Percussion Ignition
Percussion ignition can also be used to ignite the heating unit. Percussion ignition generally comprises a deformable ignition tube within which is an anvil coated with an initiator composition. Ignition is activated by mechanical impact or force.
For the initiator composition to operate satisfactorily when actuated, the material must exhibit both the proper ignition sensitivity as well as to ignite the solid fuel properly. Various initiator compositions can be used but generally consists of a mixture of readily combustible fuel such as phosphorus with an oxidizer compound for the fuel such as alkali metal chlorates and perchlorates. The initiator composition also further generally includes a powdered combustible metal such as titanium, zirconium, hafnium, thorium, aluminum, magnesium, boron, silicon or their alloys. Typically, the initiator compositions are prepared as liquid suspension in an organic or aqueous solvent for easy handling and coating the anvil and soluble binders are generally included to provide adhesion of the coating to the anvil if required.
The initiator composition can be mixed using conventional methods to provide an even blend of the constituents. Typically, all solid materials can have a particle range from a fine mesh size to a micron size or a nanometer size. By changing the ratio of the solid materials in the initiator composition, it is possible to make the final initiator composition release more or less energy, as is needed, and to be more or less sensitive to light pulses, air or oxygen and shock.
The coating of the initiator material can be applied to the anvil in various known ways. For example, the anvil can be dipped into a slurry of the initiator composition followed by drying in air or heat to remove the liquid and produce a solid adhered coating have the desired characteristic previously described. Alternately, the slurry can be sprayed or spin coated on the anvil and thereafter processed to provide a solid coating. The thickness of the coating of the initiator composition on the anvil should be such, that when the anvil is place in the ignition tube, the initiator composition is a slight distance of around a few thousandths of an inch or so, for example, 0.004 inch, for the inside wall of the ignition tube.
The anvil on which the initiator composition is disposed is typically a metal wire or rod. It should be of a suitable metallic composition such that it exhibits a high temperature resistance and low thermal conductivity, such as, for example, stainless steel. The anvil is disposed within the metal ignition tube and extended substantially coaxially. Thus, the anvil should be of a slightly smaller diameter than the inside diameter of the ignition tube so as to be spaced a slight distance, for example, about 0.05 inch or so from the inside wall thereof.
The anvil is disposed within a metal ignition tube. The ignition tube should be of readily deformable materials and can comprise a thin-walled (for example, 0.003-inch wall thickness) tube of a suitable metallic composition, such as for example, aluminum, nickel-chromium iron alloy, brass, or steel. The anvil can be held or fastened in place in the ignition tube near its outer tube by crimping or any other method typically used.
Ignition of the fuel is actuated by a forceful mechanical impact or blow applied against the side of the metal ignition tube to deform it inwardly against the coating of the initiator material on the anvil, which causes deflagration of the initiator material up through the ignition tube into the fuel coated heating unit. Various means for providing mechanic impact can be used. In certain embodiments a spring loaded impinger or striker is used to actuate the ignition.
An embodiment of a heating unit 800 comprising a percussive igniter is illustrated in
An example of the preparation of a heating unit using percussion ignition is described in Example 11. The advantages of such an ignition system over resistive ignition are that it eliminates the need for use of battery and is a very cost effective means of ignition.
Optical Ignition
Optical ignition can also be used to ignite the heating unit. Optical ignition requires the use either a light sensitive material or initiator composition and a light source for actuation of the light sensitive material or initiator composition or a very high intensity light source, e.g., a laser.
Various light sensitive initiator compositions can be used, but they generally consist of combustible materials that are light absorptive or are coated with light absorptive chemicals. Black powder and nitrocellulose powders are sufficiently light absorptive without any coatings. Metal and oxidizing agent compositions, such as those discussed above, can also be used. In certain embodiments, metals such as, for example, aluminum, zirconium, and titanium and oxidizing agents such as potassium chlorate, potassium perchlorate, copper oxide, tungsten trioxide, and molybdenum trioxide can be used. Initiator compositions that are sensitive to a specific wavelength or range of wavelengths, such as, for example, compositions that are highly absorptive in the ultraviolet region of the electromagnetic spectrum can also be used.
The initiator material can be applied directly to the fuel on the substrate or positioned elsewhere within the heating unit. In certain embodiments, initiator compositions can be within a hole in glass fiber filter that is placed adjacent to the surface of the coated fuel.
Ignition of the fuel in a heat package is actuated by transmission of a light pulse through a clear optical window to the initiator compositions. The optical window can be made of any material that readily transmits a light pulse, such as for example, glass, acrylic, or polycarbonate. The window can be positioned in any location to transmit the light to the initiator. In certain embodiments, the window forms part of the enclosure of the heating unit. In other embodiments, the window is completely contained in the system. In certain embodiments the window is part of a light guide assembly. The light guide assembly can also consist of a beam splitter. The light coming from the light source passes through the beam splitter and can directed to two or more initiator compositions located within the heating unit for initiation of two or more fuel coated substrates at the same time or in sequence. Optionally, an optical fiber can be used to fire multiple heating units at the same time. In other embodiments, the window can be coated by a material which causes the wavelength of the light which it emits to be different from the light which it receives. For example, the radiant optical source could emit ultraviolet light, and the coating could be used to give off a visible wavelength in response to the ultraviolet light.
Various means for actuating the optical ignition can be used. In certain embodiments, an electrically conductive means for generating a light pulse upon achieving a threshold voltage is provided. The electrically conductive means can be part of the heating unit itself, e.g., included in a spacer of the heating unit or separate from the heating unit. The electrically conductive means for generating a light pulse can include, for example a Xenon flash lamp, a light emitting diode, and a laser.
Several embodiments of a heating unit 900 comprising an optical ignition system are illustrated in
As shown in
Various means can be used to seal the heating unit. Sealant 906 can be an adhesive, such as double sided tape or epoxy, or any other methods for forming a seal, such as for example, welding, soldering, fastening or crimping.
In certain embodiments, the light source 911 is part of the heating unit, and can be contained within the spacer 902 contained in the heating unit 900, as shown in
An example of the preparation of a single heating unit using optical ignition is described in Example 11. Example 12 describes the preparation of a device with multiple optically ignitable heating units. One advantage of such an ignition system is that there is no need for a direct electrical connection between a battery and the initiator composition, as is required for electrical resistive heating. Additionally, the initiator composition can be ignited within the heating unit without the need for a bridgewire.
Drug Supply Unit
Certain embodiments include a drug supply unit comprising a heating unit as described herein. A drug supply unit can be used in a drug delivery device where a drug is to be thermally vaporized and then condensed for administration to a user. In certain embodiments, the drug condensate can be administered by inhalation, nasal ingestion, or topically. Drug refers to any compound for therapeutic use or non-therapeutic use, including therapeutic agents and substances. Therapeutic agent refers to any compound for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and any compound used in the mitigation or treatment of symptoms of disease. Whereas, substances refer to compounds used for a non-therapeutic use, typically for a recreational or experimental purpose.
In certain embodiments, film 110 can be applied to exterior substrate surface 106 by any appropriate method and can depend at least in part on the physical properties of the drug and the final thickness of the film. In certain embodiments, methods of applying a drug to the exterior substrate surface include, but are not limited to, brushing, dip coating, spray coating, screen printing, roller coating, inkjet printing, vapor-phase deposition, spin coating, and the like. In certain embodiments, the drug can be prepared as a solution comprising at least one solvent and applied to the exterior surface. In certain embodiments, a solvent can comprise a volatile solvent such as, for example, but not limitation, acetone or isopropanol. In certain embodiments, the drug can be applied to the exterior surface of the substrate as a melt. In certain embodiments, the drug can be applied to a support having a release coating and transferred to a substrate from the support. For drugs that are liquid at room temperature, thickening agents can be admixed with the drug to produce a viscous composition comprising the drug that can be applied to the exterior substrate surface by any appropriate method, including those described herein. In certain embodiments, a film of compound can be formed during a single application or can be formed during repeated applications to increase the final thickness of the film. In certain embodiments, the final thickness of a film of drug disposed on the exterior substrate surface can be less than 50 μm, in certain embodiments less than 20 μm and in certain embodiments less than 10 μm, in certain embodiments the film thickness can range from 0.02 μm to 20 μm, and in certain embodiments can range from 0.1 μm to 10 μm.
In certain embodiments, the film can comprise a therapeutically effective amount of at least one drug. Therapeutically effective amount refers to an amount sufficient to affect treatment when administered to a patient or user in need of treatment. Treating or treatment of any disease, condition, or disorder refers to arresting or ameliorating a disease, condition or disorder, reducing the risk of acquiring a disease, condition or disorder, reducing the development of a disease, condition or disorder or at least one of the clinical symptoms of the disease, condition or disorder, or reducing the risk of developing a disease, condition or disorder or at least one of the clinical symptoms of a disease or disorder. Treating or treatment also refers to inhibiting the disease, condition or disorder, either physically, e.g. stabilization of a discernible symptom, physiologically, e.g., stabilization of a physical parameter, or both, and inhibiting at least one physical parameter that may not be discernible to the patient. Further, treating or treatment refers to delaying the onset of the disease, condition or disorder or at least symptoms thereof in a patient which may be exposed to or predisposed to a disease, condition or disorder even though that patient does not yet experience or display symptoms of the disease, condition or disorder. In certain embodiments, the drug film can comprise one or more pharmaceutically acceptable carriers, adjuvants, and/or excipients. Pharmaceutically acceptable refers to approved or approvable by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopoeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.
As shown in
As shown in
The drug supply unit is configured such that the solid fuel heats a portion of the exterior surface of the substrate to a temperature sufficient to thermally vaporize the drug in certain embodiments within at least 3 seconds following ignition of the solid fuel, in other embodiments within 1 second following ignition of the solid fuel, in other embodiments within 800 milliseconds following ignition of the solid fuel, in other embodiments within 500 milliseconds following ignition of the solid fuel, and in other embodiments within 250 milliseconds following ignition of the solid fuel.
In certain embodiments, a drug supply unit can generate an aerosol comprising a drug that can be inhaled directly by a user and/or can be mixed with a delivery vehicle, such as a gas, to produce a stream for delivery, e.g., via a spray nozzle, to a topical site for a variety of treatment regimens, including acute or chronic treatment of a skin condition, administration of a drug to an incision site during surgery, or to an open wound.
In certain embodiments, rapid vaporization of a drug film can occur with minimal thermal decomposition of the drug. For example, in certain embodiments, less than 10% of the drug is decomposed during thermal vaporization, and in certain embodiments, less than 5% of the drug is decomposed during thermal vaporization. In certain embodiments, a drug can undergo a phase transition to a liquid state and then to a gaseous state, or can sublime, i.e., pass directly from a solid state to a gaseous state. In certain embodiments, a drug can include a pharmaceutical compound. In certain embodiments, the drug can comprise a therapeutic compound or a non-therapeutic compound. A non-therapeutic compound refers to a compound that can be used for recreational, experimental, or pre-clinical purposes. Classes of drugs that can be used include, but are not limited to, anesthetics, anticonvulsants, antidepressants, antidiabetic agents, antidotes, antiemetics, antihistamines, anti-infective agents, antineoplastics, antiparkisonian drugs, antirheumatic agents, antipsychotics, anxiolytics, appetite stimulants and suppressants, blood modifiers, cardiovascular agents, central nervous system stimulants, drugs for Alzheimer's disease management, drugs for cystic fibrosis management, diagnostics, dietary supplements, drugs for erectile dysfunction, gastrointestinal agents, hormones, drugs for the treatment of alcoholism, drugs for the treatment of addiction, immunosuppressives, mast cell stabilizers, migraine preparations, motion sickness products, drugs for multiple sclerosis management, muscle relaxants, nonsteroidal anti-inflammatories, opioids, other analgesics and stimulants, opthalmic preparations, osteoporosis preparations, prostaglandins, respiratory agents, sedatives and hypnotics, skin and mucous membrane agents, smoking cessation aids, Tourette's syndrome agents, urinary tract agents, and vertigo agents.
Examples of anesthetic include ketamine and lidocaine.
Examples of anticonvulsants include compounds from one of the following classes: GABA analogs, tiagabine, vigabatrin; barbiturates such as pentobarbital; benzodiazepines such as clonazepam; hydantoins such as phenytoin; phenyltriazines such as lamotrigine; miscellaneous anticonvulsants such as carbamazepine, topiramate, valproic acid, and zonisamide.
Examples of antidepressants include amitriptyline, amoxapine, benmoxine, butriptyline, clomipramine, desipramine, dosulepin, doxepin, imipramine, kitanserin, lofepramine, medifoxamine, mianserin, maprotoline, mirtazapine, nortriptyline, protriptyline, trimipramine, venlafaxine, viloxazine, citalopram, cotinine, duloxetine, fluoxetine, fluvoxamine, milnacipran, nisoxetine, paroxetine, reboxetine, sertraline, tianeptine, acetaphenazine, binedaline, brofaromine, cericlamine, clovoxamine, iproniazid, isocarboxazid, moclobemide, phenyhydrazine, phenelzine, selegiline, sibutramine, tranylcypromine, ademetionine, adrafinil, amesergide, amisulpride, amperozide, benactyzine, bupropion, caroxazone, gepirone, idazoxan, metralindole, milnacipran, minaprine, nefazodone, nomifensine, ritanserin, roxindole, S-adenosylmethionine, escitalopram, tofenacin, trazodone, tryptophan, and zalospirone.
Examples of antidiabetic agents include pioglitazone, rosiglitazone, and troglitazone.
Examples of antidotes include edrophonium chloride, flumazenil, deferoxamine, nalmefene, naloxone, and naltrexone.
Examples of antiemetics include alizapride, azasetron, benzquinamide, bromopride, buclizine, chlorpromazine, cinnarizine, clebopride, cyclizine, diphenhydramine, diphenidol, dolasetron, droperidol, granisetron, hyoscine, lorazepam, dronabinol, metoclopramide, metopimazine, ondansetron, perphenazine, promethazine, prochlorperazine, scopolamine, triethylperazine, trifluoperazine, triflupromazine, trimethobenzamide, tropisetron, domperidone, and palonosetron.
Examples of antihistamines include astemizole, azatadine, brompheniramine, carbinoxamine, cetrizine, chlorpheniramine, cinnarizine, clemastine, cyproheptadine, dexmedetomidine, diphenhydramine, doxylamine, fexofenadine, hydroxyzine, loratidine, promethazine, pyrilamine and terfenidine.
Examples of anti-infective agent include compounds selected from one of the following classes: antivirals such as efavirenz; AIDS adjunct agents such as dapsone; aminoglycosides such as tobramycin; antifungals such as fluconazole; antimalarial agents such as quinine; antituberculosis agents such as ethambutol; P-lactams such as cefinetazole, cefazolin, cephalexin, cefoperazone, cefoxitin, cephacetrile, cephaloglycin, cephaloridine; cephalosporins, such as cephalosporin C, cephalothin; cephamycins such as cephamycin A, cephamycin B, and cephamycin C, cephapirin, cephradine; leprostatics such as clofazimine; penicillins such as ampicillin, amoxicillin, hetacillin, carfecillin, carindacillin, carbenicillin, amylpenicillin, azidocillin, benzylpenicillin, clometocillin, cloxacillin, cyclacillin, methicillin, nafcillin, 2-pentenylpenicillin, penicillin N, penicillin O, penicillin S, penicillin V, dicloxacillin; diphenicillin; heptylpenicillin; and metampicillin; quinolones such as ciprofloxacin, clinafloxacin, difloxacin, grepafloxacin, norfloxacin, ofloxacine, temafloxacin; tetracyclines such as doxycycline and oxytetracycline; miscellaneous anti-infectives such as linezolide, trimethoprim and sulfamethoxazole.
Examples of anti-neoplastic agents include droloxifene, tamoxifen, and toremifene.
Examples of antiparkisonian drugs include amantadine, baclofen, biperiden, benztropine, orphenadrine, procyclidine, trihexyphenidyl, levodopa, carbidopa, andropinirole, apomorphine, benserazide, bromocriptine, budipine, cabergoline, eliprodil, eptastigmine, ergoline, galanthamine, lazabemide, lisuride, mazindol, memantine, mofegiline, pergolide, piribedil, pramipexole, propentofylline, rasagiline, remacemide, ropinerole, selegiline, spheramine, terguride, entacapone, and tolcapone.
Examples of antirheumatic agents include diclofenac, hydroxychloroquine and methotrexate.
Examples of antipsychotics include acetophenazine, alizapride, amisulpride, amoxapine, amperozide, aripiprazole, benperidol, benzquinamide, bromperidol, buramate, butaclamol, butaperazine, carphenazine, carpipramine, chlorpromazine, chlorprothixene, clocapramine, clomacran, clopenthixol, clospirazine, clothiapine, clozapine, cyamemazine, droperidol, flupenthixol, fluphenazine, fluspirilene, haloperidol, loxapine, melperone, mesoridazine, metofenazate, molindrone, olanzapine, penfluridol, pericyazine, perphenazine, pimozide, pipamerone, piperacetazine, pipotiazine, prochlorperazine, promazine, quetiapine, remoxipride, risperidone, sertindole, spiperone, sulpiride, thioridazine, thiothixene, trifluperidol, triflupromazine, trifluoperazine, ziprasidone, zotepine, and zuclopenthixol.
Examples of anxiolytics include alprazolam, bromazepam, oxazepam, buspirone, hydroxyzine, mecloqualone, medetomidine, metomidate, adinazolam, chlordiazepoxide, clobenzepam, flurazepam, lorazepam, loprazolam, midazolam, alpidem, alseroxlon, amphenidone, azacyclonol, bromisovalum, captodiamine, capuride, carbcloral, carbromal, chloral betaine, enciprazine, flesinoxan, ipsapiraone, lesopitron, loxapine, methaqualone, methprylon, propanolol, tandospirone, trazadone, zopiclone, and zolpidem.
An example of an appetite stimulant is dronabinol.
Examples of appetite suppressants include fenfluramine, phentermine and sibutramine.
Examples of blood modifiers include cilostazol and dipyridamol.
Examples of cardiovascular agents include benazepril, captopril, enalapril, quinapril, ramipril, doxazosin, prazosin, clonidine, labetolol, candesartan, irbesartan, losartan, telmisartan, valsartan, disopyramide, flecanide, mexiletine, procainamide, propafenone, quinidine, tocainide, amiodarone, dofetilide, ibutilide, adenosine, gemfibrozil, lovastatin, acebutalol, atenolol, bisoprolol, esmolol, metoprolol, nadolol, pindolol, propranolol, sotalol, diltiazem, nifedipine, verapamil, spironolactone, bumetanide, ethacrynic acid, furosemide, torsemide, amiloride, triamterene, and metolazone.
Examples of central nervous system stimulants include amphetamine, brucine, caffeine, dexfenfluramine, dextroamphetamine, ephedrine, fenfluramine, mazindol, methyphenidate, pemoline, phentermine, sibutramine, and modafinil.
Examples of drugs for Alzheimer's disease management include donepezil, galanthamine and tacrin.
Examples of drugs for cystic fibrosis management include CPX, IBMX, XAC and analogues; 4-phenylbutyric acid; genistein and analogous isoflavones; and milrinone.
Examples of diagnostic agents include adenosine and aminohippuric acid.
Examples of dietary supplements include melatonin and vitamin-E.
Examples of drugs for erectile dysfunction include tadalafil, sildenafil, vardenafil, apomorphine, apomorphine diacetate, phentolamine, and yohimbine.
Examples of gastrointestinal agents include loperamide, atropine, hyoscyamine, famotidine, lansoprazole, omeprazole, and rebeprazole.
Examples of hormones include: testosterone, estradiol, and cortisone.
Examples of drugs for the treatment of alcoholism include naloxone, naltrexone, and disulfiram.
Examples of drugs for the treatment of addiction it is buprenorphine.
Examples of immunosupressives includemycophenolic acid, cyclosporin, azathioprine, tacrolimus, and rapamycin.
Examples of mast cell stabilizers include cromolyn, pemirolast, and nedocromil.
Examples of drugs for migraine headache include almotriptan, alperopride, codeine, dihydroergotamine, ergotamine, eletriptan, frovatriptan, isometheptene, lidocaine, lisuride, metoclopramide, naratriptan, oxycodone, propoxyphene, rizatriptan, sumatriptan, tolfenamic acid, zolmitriptan, amitriptyline, atenolol, clonidine, cyproheptadine, diltiazem, doxepin, fluoxetine, lisinopril, methysergide, metoprolol, nadolol, nortriptyline, paroxetine, pizotifen, pizotyline, propanolol, protriptyline, sertraline, timolol, and verapamil.
Examples of motion sickness products include diphenhydramine, promethazine, and scopolamine.
Examples of drugs for multiple sclerosis management include bencyclane, methylprednisolone, mitoxantrone, and prednisolone.
Examples of muscle relaxants include baclofen, chlorzoxazone, cyclobenzaprine, methocarbamol, orphenadrine, quinine, and tizanidine.
Examples of nonsteroidal anti-inflammatory drugs include aceclofenac, acetaminophen, alminoprofen, amfenac, aminopropylon, amixetrine, aspirin, benoxaprofen, bromfenac, bufexamac, carprofen, celecoxib, choline, salicylate, cinchophen, cinmetacin, clopriac, clometacin, diclofenac, diflunisal, etodolac, fenoprofen, flurbiprofen, ibuprofen, indomethacin, indoprofen, ketoprofen, ketorolac, mazipredone, meclofenamate, nabumetone, naproxen, parecoxib, piroxicam, pirprofen, rofecoxib, sulindac, tolfenamate, tolmetin, and valdecoxib.
Examples of opioid drugs include alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, carbiphene, cipramadol, clonitazene, codeine, dextromoramide, dextropropoxyphene, diamorphine, dihydrocodeine, diphenoxylate, dipipanone, fentanyl, hydromorphone, L-alpha acetyl methadol, lofentanil, levorphanol, meperidine, methadone, meptazinol, metopon, morphine, nalbuphine, nalorphine, oxycodone, papaveretum, pethidine, pentazocine, phenazocine, remifentanil, sufentanil, and tramadol.
Examples of other analgesic drugs include apazone, benzpiperylon, benzydramine, caffeine, clonixin, ethoheptazine, flupirtine, nefopam, orphenadrine, propacetamol, and propoxyphene.
Examples of opthalmic preparation drugs include ketotifen and betaxolol.
Examples of osteoporosis preparation drugs alendronate, estradiol, estropitate, risedronate and raloxifene.
Examples of prostaglandin drugs include epoprostanol, dinoprostone, misoprostol, and alprostadil.
Examples of respiratory agents include albuterol, ephedrine, epinephrine, fomoterol, metaproterenol, terbutaline, budesonide, ciclesonide, dexamethasone, flunisolide, fluticasone propionate, triamcinolone acetonide, ipratropium bromide, pseudoephedrine, theophylline, montelukast, zafirlukast, ambrisentan, bosentan, enrasentan, sitaxsentan, tezosentan, iloprost, treprostinil, and pirfenidone
Examples of sedative and hypnotic drugs include butalbital, chlordiazepoxide, diazepam, estazolam, flunitrazepam, flurazepam, lorazepam, midazolam, temazepam, triazolam, zaleplon, zolpidem, and zopiclone.
Examples of skin and mucous membrane agents include isotretinoin, bergapten and methoxsalen.
Examples of smoking cessation aids include nicotine and varenicline.
An example of a Tourette's syndrome agent includes pimozide.
Examples of urinary tract agents include tolteridine, darifenicin, propantheline bromide, and oxybutynin.
Examples of vertigo agents include betahistine and meclizine.
In certain embodiments, a drug can further comprise substances to enhance, modulate and/or control release, aerosol formation, intrapulmonary delivery, therapeutic efficacy, therapeutic potency, stability, and the like. For example, to enhance therapeutic efficacy a drug can be co-administered with one or more active agents to increase the absorption or diffusion of the first drug through the pulmonary alveoli, or to inhibit degradation of the drug in the systemic circulation. In certain embodiments, a drug can be co-administered with active agents having pharmacological effects that enhance the therapeutic efficacy of the drug. In certain embodiments, a drug can comprise compounds that can be used in the treatment of one or more diseases, conditions, or disorders. In certain embodiments, a drug can comprise more than one compound for treating one disease, condition, or disorder, or for treating more than one disease, condition, or disorder.
Thin Film Drug Supply Unit
An embodiment of a thin film drug supply unit is illustrated in
As shown, first and second substrates 510 include an area comprising solid fuel 512 disposed on the interior surface, and an area comprising a drug 514 to be vaporized disposed on the exterior surface. First and second substrates 510 can comprise a thermally conductive material such as those described herein, including, for example, metals, ceramics, and thermally conductive polymers. In certain embodiments, substrates 510 can comprise a metal, such as, but not limited to, stainless steel, copper, aluminum, and nickel, or an alloy thereof. Substrates can have one or more layers, and the multiple layers can comprise different materials. For example, a substrate can comprise multiple layers of laminated metal foils, and/or can comprise thin films of one or more materials deposited on the surface. The multiple layers can be used for example to determine the thermal properties of the substrate and/or can be used to determine the reactivity of the surface with respect to a compound disposed on the exterior surface. A multilayer substrate can have regions comprising different materials. The thickness of substrates 510 can be thin to facilitate heat transfer from the interior to the exterior surface and/or to minimize the thermal mass of the device. In certain embodiments, a thin substrate can facilitate rapid and homogeneous heating of the exterior surface with a lesser amount of solid fuel compared to a thicker substrate. Substrate 510 can also provide structural support for solid fuel 512 and drug film 514. In certain embodiments, substrates 510 can comprise a metal foil. In certain embodiments, the thickness of substrates 510 can range from 0.001 inches to 0.020 inches, in certain embodiments from 0.001 inches to 0.010 inches, in certain embodiments from 0.002 inches to 0.006 inches, and in certain embodiments from 0.002 inches to 0.005 inches. The use of lesser amounts of solid fuel can facilitate control of the heating process as well as facilitate miniaturization of a drug supply unit.
In certain embodiments, the thickness of substrates 510 can vary across the surface. For example, a variable thickness can be useful for controlling the temporal and spatial characteristics of heat transfer and/or to facilitate sealing of the edges of substrates 510, for example, to spacer 518, opposing substrate 510, or to another support (not shown). In certain embodiments, substrates 510 can exhibit a homogeneous or nearly homogeneous thickness in the region of the substrate on which solid fuel 512 and drug 514 are disposed to facilitate achieving a homogeneous temperature across that region of the substrate on which the solid fuel is disposed. Homogeneous heating of the substrate can facilitate the production of an aerosol comprising a high purity of a drug or pharmaceutical composition and maximize the yield of drug initially deposited on the substrate forming an aerosol.
Substrates 510 can comprise an area of solid fuel 512 disposed on the interior surface, e.g. the surface facing opposing substrate 510. An appropriate amount of solid fuel 512 can in part be determined by the thermal vaporization or sublimation temperature of the drug, the amount of drug to be vaporized, the thickness and thermal conductivity of the substrate, the composition of the solid fuel, and the temporal characteristics of the intended thermal vaporization process. Solid fuel 512 can be applied to substrate 510 using any appropriate method. For example, solid fuel 512 can be applied to substrate 510 by brushing, dip coating, screen printing, roller coating, spray coating, inkjet printing, stamping, spin coating, and the like. To facilitate processing, solid fuel 510 can comprise at least one additive material, and/or a solvent, as disclosed herein. In certain embodiments, solid fuel 512 can be formed as a preformed sheet that can be cut to a specific dimension and subsequently applied to substrate 510. In certain embodiments, the solid fuel can be applied to a support, and transferred to a substrate as a preformed section.
Solid fuel 512 can be applied to a portion of substrates 510 as a thin film or layer. The thickness of the thin layer of solid fuel 512, and the composition of solid fuel 512 can determine the maximum temperature as well as the temporal and spatial dynamics of the temperature profile produced by the burning of the solid fuel.
Studies using thin solid fuel layers having a thickness ranging from 0.001 inches to 0.005 inches demonstrate that the maximum temperature reached by a thin film substrate on which the solid fuel is disposed can be linear with the mass of solid fuel applied. For example, as shown in
Measurements of the substrate surface temperature demonstrate that thin coatings of a solid fuel comprising a metal reducing agent and a metal-containing oxidizing agent can produce homogenous heating. A temperature profile of a substrate forming a heating unit substantially as shown in
Measurements of the substrate surface temperature after firing demonstrate that thin coatings or layers of a solid fuel comprising a metal reducing agent and a metal-containing oxidizing agent can produce uniformity of temperature on the exterior surface of the substrate. Uniformity of temperature is defined herein to exist when the temperature in degrees Celsius of the exterior surface of the substrate, corresponding to the fuel coated area of the interior surface of the substrate, is within a standard deviation of 50° C. from the average surface temperature obtained, as measured within 100 milliseconds after completion of propagation of the ignited fuel flame front. A temperature profile of a substrate forming a heating unit substantially as shown in
In certain applications, such as for example, vaporization of a drug off the substrate of a heating unit, uniformity of heating of the substrate is critical as it facilitates the production of an aerosol comprising a high purity drug or pharmaceutical composition and maximizes the yield of drug initially deposited on the substrate forming an aerosol.
In certain embodiments, solid fuel 512 can comprise a mixture of Zr/MoO3, Zr/Fe2O3, Al/MoO3, or Al/Fe2O3. In certain embodiments, the amount of metal reducing agent can range from 60 wt % to 90 wt %, and the amount of metal-containing oxidizing agent can range from 40 wt % to 10 wt %. In certain embodiments, higher ratios of metal reducing agent can cause the solid fuel to burn slower and at a lower temperature, whereas lower ratios of metal reducing agent can cause the solid fuel to burn faster and reach a higher maximum temperature. Regardless of the weight percent ratios of the metal reducing agent and metal-containing oxidizing agent, a solid fuel can comprise a stoichiometric amount of metal reducing agent and metal-containing oxidizing agent. For example, the balanced Zr:Fe2O3 metal oxidation-reduction reaction can be written as:
3Zr+2Fe2O3→3 ZrO2+4Fe
A stoichiometric amount of Zr:Fe2O3 for this reaction is 1:1.67 by weight.
Drug 514 can be disposed on the exterior surface of substrates 510. The amount of drug 514 disposed on the exterior surface of substrate 510 can be any appropriate amount. For example, the amount of drug 514 can be a therapeutically effective amount. A therapeutically effective amount can be determined by the potency of the drug, the clinical indications, and the mode of administration. In certain embodiments, thin film drug supply unit can be configured to thermally vaporize more than 95% of the drug, and in certain embodiments, greater than 98% of the drug, with minimal degradation of the drug. The aerosol formed using a drug supply unit can comprise greater than 90% of a drug applied to a substrate, and in certain embodiments greater than 95% of a drug applied to a substrate. The yield and purity of the aerosol can be controlled by and selected based on the temporal characteristics and magnitude of the thermal impulse transferred to the compound.
The relationship of the yield and purity of an aerosol comprising a pharmaceutical compound on the substrate temperature and mass of solid fuel for certain embodiments is shown in
The percent purity, with respect to the aerosol purity, refers to the fraction of drug composition in the aerosol/the fraction of drug composition in the aerosol plus drug degradation products times 100. Thus purity is relative with regard to the purity of the starting material. For example, when the starting drug or drug composition used for substrate coating contained detectable impurities, the reported purity of the aerosol does not include those impurities present in the starting material that were also found in the aerosol, e.g., in certain cases if the starting material contained a 1% impurity and the aerosol was found to contain the identical 1% impurity, the aerosol purity may nevertheless be reported as >99% pure, reflecting the fact that the detectable 1% purity was not produced during the vaporization-condensation aerosol generation process.
Factors that can reduce the percent purity of the aerosol include degradation of the drug during thermal vaporization. Depending at least in part on the composition and thermal properties of a particular drug or pharmaceutical composition, the appropriate thermal vaporization temperature to produce an aerosol comprising the particular drug or pharmaceutical composition having high yield and purity can be determined as set forth in U.S. application Ser. No. 10/718,982, filed Nov. 20, 2003.
Drug 514 can be applied to substrate 510 using any appropriate method, such as for example, brushing, dip coating, screen printing, roller coating, spray coating, inkjet printing, stamping, vapor deposition, and the like. Drug 514 can also be applied to a support having a release layer and transferred to substrate 510. Drug 514 can be suspended in a volatile solvent such as, for example, but not limited to, acetone or isopropanol to facilitate application. A volatile solvent can be removed at room temperature or at elevated temperature, with or without application of a vacuum. In certain embodiments, the solvent can comprise a pharmaceutically acceptable solvent. In certain embodiments, residual solvent can be reduced to a pharmaceutically acceptable level.
Drug 514 can be disposed on substrate 510 in any appropriate form such as a solid, viscous liquid, liquid, crystalline solid, or powder. In certain embodiments, the film of drug can be crystallized after disposition on the substrate.
As shown in
The electrically resistive heating element can be connected to electrical conductors. The heating element can be soldered or electrically connected to conductors, such as, Cu conductors or graphite ink traces, disposed on an electrically insulating substrate, such as a polyimide, polyester, or fluoropolymer. The conductors can be disposed between two opposing layers of the electrically insulating material such as flexible or rigid printed circuit board materials. The heating element on which an initiator composition is disposed can be exposed through an opening in the end of ignition assembly 520.
Igniter 520 can be positioned with respect to solid fuel 512 such that sparks produced by initiator composition 522 can be directed toward solid fuel area 512, causing solid fuel 512 to ignite and burn. Initiator composition 522 can be located in any position such that sparks produced by the initiator can cause solid fuel 512 to ignite. The location of initiator composition 522 with respect to solid fuel 512 can determine the direction in which solid fuel 512 burns. For example, initiator composition 522 can be located to cause solid fuel 512 to burn in any direction with respect to the airflow including in the same direction of airflow, opposite the direction of airflow, or normal the direction of airflow. The direction of solid fuel burn with respect to airflow can influence the average particle diameter of particulates comprising the thermally vaporized drug forming the aerosol. For example, in certain embodiments, solid fuel burn opposite the direction of airflow can produce smaller diameter particles than when the direction of solid fuel burn is in the same direction as the airflow. The dynamics of solid fuel burn can be influenced by other parameters such as the spatial and temporal characteristics of the surface temperature, and the extent to which vaporized drug is redeposited on the substrate and/or other surfaces such as a housing in which the drug supply unit is incorporated.
In certain embodiments, thin film drug supply unit 500 can comprise more than one igniter 520 and/or each igniter 520 can comprise more than one initiator composition 522.
In certain embodiments, it can be useful to minimize the amount of initiator composition used, so as to reduce the amount of gas and other reaction products potentially generated by the initiator composition during burn.
In certain embodiments, igniter 520 can comprise a mechanism configured to direct transmitted radiation to an initiator composition capable of absorbing and being heated by the transmitted radiation, to produce sparks. For example, in certain embodiments, the radiation can be infrared, visible, or ultraviolet radiation such as produced by a diode laser, light emitting diode, or flashlamp. Radiation produced by a radiation source can be transmitted through a waveguide such as an optical fiber, and directed to an initiator or the radiation source can be incorporated into the ignition assembly 522 with electrical conductors for connecting to an external power source. The transmission device can include elements such as lenses for focusing the transmitted radiation onto the initiator composition. In certain embodiments, the radiation can be directed to an initiator composition disposed within the heating unit through a window. The transmitted radiation can be directed onto an absorber or a material capable of absorbing the radiation, which can be the initiator composition, or an element on which the initiator composition is disposed. In certain embodiments, the initiator composition can comprise at least one metal such as, but not limited to, zirconium, titanium, or aluminum, and at least one solid oxidizer such as, but not limited to, MoO3, KClO4, CuO, or WO3. The initiator composition can comprise any of those disclosed herein.
As shown in
In certain embodiments, spacer 518 can comprise a thermal insulator such that the spacer does not contribute to the thermal mass of the thin film drug supply unit thereby facilitating heat transfer to the substrate on which drug 514 is disposed. Thermal insulators or impulse absorbing materials such as mats of glass, silica, ceramic, carbon, or high temperature resistant polymer fibers can be used. In certain embodiments, spacer 518 can be a thermal conductor such that the spacer functions as a thermal shunt to control the temperature of the substrate.
Substrates 510, spacer 518 and igniter 520 can be sealed. Sealing can retain any reactants and reaction products released by burning of initiator composition 522 and solid fuel 514, as well as provide a self-contained unit. As shown in
In certain embodiments, the elements forming the thin film drug supply unit 500 can be assembled and sealed using thermoplastic or thermoset molding methods such as insert molding and transfer molding.
An appropriate sealing method can, at least in part be determined by the materials forming substrate 510 and spacer 518. In certain embodiments, drug supply unit 500 can be sealed to withstand a maximum pressure of less than 50 psig. In certain embodiments less than 20 psig, and in certain embodiments less than 10 psig. In certain embodiments, the materials used to form the seal can maintain structural integrity at the temperature reached by the article. In certain embodiments, the materials used can exhibit minimal degradation and produce minimal gaseous reaction products at the temperature reached by the heating unit.
Multidose Drug Supply Units
In certain embodiments, a drug supply unit can be configured for use in single-use devices or in multi-use devices.
Embodiments of thin film drug supply units are schematically illustrated in
In certain embodiments, tape 650 can comprise an upper and lower layer (not shown) configured to physically and/or environmentally protect compound 610 and solid fuel 620. The upper and/or lower protective layers can comprise, for example, a metal foil, a polymer, or can comprise a multilayer comprising metal foil and polymers. In certain embodiments, protective layers can exhibit low permeability to oxygen, moisture, and/or corrosive gases. All or portions of a protective layer can be removed prior to use to expose compound 610 and solid fuel 620. To vaporize compound 610, solid fuel 620 can be ignited by energy from an external source (not shown) to generate heat that can be conducted through second layer 602 to thermally vaporize compound 610. Examples of initiators include those discussed herein such as, but not limited to, sparks or electrical resistance heating. Use of a protective layer can facilitate use of drug 610 in the form of a powder or liquid.
In an exemplary operation, tape 670 can be advanced to locate at least one region comprising drug 610 within an airway (not shown) and to connect respective electrical contacts 680, with a power source (not shown). Upon activation of the power source, the electrical current can heat resistive element 682 to ignite initiator composition 630 and produce sparks. Sparks directed across gap 645 can ignite solid fuel 620. Heat generated by the ignition of solid fuel 620 can be conducted through second layer 602 thermally vaporizing compound 610 to form an aerosol comprising drug 610 within the airway.
Certain embodiments of another drug supply article configured for the delivery of multiple doses is illustrated in
Drug Delivery Devices
Certain embodiments include drug delivery devices comprising a housing defining an airway, a heating unit as disclosed herein, a drug disposed on a portion of the exterior surface of a substrate of the heating unit, wherein the portion of the exterior surface comprising the drug is configured to be disposed within the airway, and an initiator configured to ignite the solid fuel. Drug delivery devices can incorporate the heating units and drug supply units disclosed herein. The drug delivery device can comprise a housing defining an airway. The housing can define an airway having any appropriate shape or dimensions and can comprise at least one inlet and at least one outlet. The dimensions of an airway can at least in part be determined by the volume of air that can be inhaled through the mouth or the nostrils by a user in a single inhalation, the intended rate of airflow through the airway, and/or the intended airflow velocity at the surface of the substrate that is coupled to the airway and on which a drug is disposed. In certain embodiments, airflow can be generated by a patient inhaling with the mouth on the outlet of the airway, and/or by inhaling with the nostrils on the outlet of the airway. In certain embodiments, airflow can be generated by injecting air or a gas into the inlet such as for example, by mechanically compressing a flexible container filled with air and/or gas, or by releasing pressurized air and/or gas into the inlet of the airway. Generating an airflow by injecting air and/or gas into the airway can be useful in drug delivery devices intended for topical administration of an aerosol comprising a drug.
In certain embodiments, a housing can be dimensioned to provide an airflow velocity through the airway sufficient to produce an aerosol of a drug during thermal vaporization. In certain embodiments, the airflow velocity can be at least 1 m/sec in the vicinity of the substrate on which the drug is disposed.
In certain embodiments, a housing can be dimensioned to provide a certain airflow rate through the airway. In certain embodiments, the airflow rate through the airway can range from 10 L/min to 120 L/min. In certain embodiments, an airflow rate ranging from 10 L/min to 120 L/min can be produced during inhalation by a user when the outlet exhibits a cross-sectional area ranging from 0.1 cm2 to 20 cm2. In certain embodiments, the cross-sectional area of the outlet can range from 0.5 cm2 to 5 cm2, and in certain embodiments, from 1 cm2 to 2 cm2.
In certain embodiments, an airway can comprise one or more airflow control valves to control the airflow rate and airflow velocity in airway. In certain embodiments, an airflow control valve can comprise, but is not limited to, at least one valve such as an umbrella valve, a reed valve, a flapper valve, or a flapping valve that bends in response to a pressure differential, and the like. In certain embodiments, an airflow control valve can be located at the outlet of the airway, at the inlet of the airway, within the airway, and/or can be incorporated into the walls of housing defining the airway. In certain embodiments, an airflow control valve can be actively controlled, for example can be activated electronically such that a signal provided by a transducer located within the airway can control the position of the valve; or passively controlled, such as, for example, by a pressure differential between the airway and the exterior of the device.
Certain embodiments of drug delivery devices configured for inhalation delivery of thermal vapor generated from a drug supply unit are illustrated in
Methods for Producing and Using Aerosols
Certain embodiments include methods of producing an aerosol of a compound using the heating units, drug supply units, and drug delivery devices disclosed herein. In certain embodiments, the aerosol produced by an apparatus can comprise a therapeutically effective amount of a drug. The temporal and spatial characteristics of the heat applied to thermally vaporize the compound disposed on the substrate and the air flow rate can be selected to produce an aerosol comprising a drug having certain characteristics. For example, for intrapulmonary delivery it is known that aerosol particles having a mean mass aerodynamic diameter ranging from 0.01 μm to 0.1 μm and ranging from 1 μm to 3.5 μm can facilitate efficient transfer of drugs from alveoli to the systemic circulation. In applications wherein the aerosol is applied topically, the aerosol can have the same or different characteristics.
Certain embodiments include methods for producing an aerosol comprising: (i) providing an airflow over a drug disposed on a portion of an exterior surface of a substrate forming a drug supply unit, wherein the drug supply unit comprises a heating unit as disclosed herein and the drug disposed on a portion of the exterior surface of the substrate, wherein the portion of the exterior surface comprising the drug is disposed within the airway; and an initiator composition configured to ignite the solid chemical fuel; and (ii) thermally vaporizing and condensing the drug to form an aerosol of the drug in the airway. In certain embodiments, the drug is disposed on the surface of the substrate as a thin film.
Certain embodiments include methods of treating a disease in a patient in need of such treatment comprising administering to the patient an aerosol comprising a therapeutically effective amount of a drug, wherein the aerosol is produced by the methods and devices disclosed herein. The aerosol can be administered by inhalation through the mouth, by nasal ingestion, and/or by topical application.
Other embodiments will be apparent to those skilled in the art from consideration and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only.
In the examples below, the following abbreviations have the following meanings. If an abbreviation is not defined, it has its generally accepted meaning.
The following procedure was used to prepare solid fuel coatings comprising 76.16% Zr:19.04% MoO3:4.8% LAPONITE® RDS.
To prepare wet Zirconium (Zr), the as-obtained suspension of Zr in DI water (Chemetall, Germany) was agitated on a roto-mixer for 30 minutes. Ten to 40 mL of the wet Zr was dispensed into a 50 mL centrifuge tube and centrifuged (Sorvall 6200RT) for 30 minutes at 3,200 rpm. The DI water was removed to leave a wet Zr pellet.
To prepare a 15% LAPONITE® RDS solution, 85 grams of DI water was added to a beaker. While stirring, 15 grams of LAPONITE® RDS (Southern Clay Products, Gonzalez, Tex.) was added, and the suspension stirred for 30 minutes.
The reactant slurry was prepared by first removing the wet Zr pellet as previously prepared from the centrifuge tube and placed in a beaker. Upon weighing the wet Zr pellet, the weight of dry Zr was determined from the following equation: Dry Zr(g)=0.8234(Wet Zr(g))−0.1059.
The amount of molybdenum trioxide to provide a 80:20 ratio of Zr to MoO3 was then determined, e.g, MoO3=Dry Zr(g)/4, and the appropriate amount of MoO3 powder (Accumet, NY) was added to the beaker containing the wet Zr to produce a wet Zr:MoO3 slurry. The amount of LAPONITE® RDS to obtain a final weight percent ratio of dry components of 76.16% Zr:19.04% MoO3:4.80% LAPONITE® RDS was determined. Excess water to obtain a reactant slurry comprising 40% DI water was added to the wet Zr and MoO3 slurry. The reactant slurry was mixed for 5 minutes using an IKA Ultra-Turrax mixing motor with a S25N-8G dispersing head (setting 4). The amount of 15% LAPONITE® RDS previously determined was then added to the reactant slurry, and mixed for an additional 5 minutes using the IKA Ultra-Turrax mixer. The reactant slurry was transferred to a syringe and stored for at least 30 minutes prior to coating.
The Zr:MoO3:LAPONITE® RDS reactant slurry was then coated onto stainless steel foils. Stainless steel foils were first cleaned by sonication for 5 minutes in a 3.2% bv solution of Ridoline 298 in DI water at 60° C. Stainless steel foils were masked with 0.215 inch wide MYLAR® such that the center portion of each 0.004 inch thick 304 stainless steel foil was exposed. The foils were placed on a vacuum chuck having 0.008 inch thick shims at the edges. Two (2) mL of the reactant slurry was placed at one edge of the foil. Using a Sheen Auto-Draw Automatic Film Applicator 1137 (Sheen Instruments) the reactant slurry was coated onto the foils by drawing a #12 coating rod at an auto-draw coating speed of up to 50 mm/sec across the surface of the foils to deposit approximately an 0.006 inch thick layer of the Zr:MoO3:LAPONITE® RDS reactant slurry. The coated foils were then placed in a 40° C. forced-air convection oven and dried for at least 2 hours. The masks were then removed from the foils to leave a coating of solid fuel on the center section of each foil.
The solid fuel coatings comprising LAPONITE® RDS adhered to the stainless steel foil surface and maintained physical integrity following mechanical and environmental testing including temperature cycling (−25° C.40° C.), accelerated humidity exposure (40° C./75% RH), drop testing, impact testing, and flexure testing.
Thin film heating units were used to measure the peak internal pressure and the peak temperature of the exterior surface of the substrate following ignition of the solid fuel.
The thin film heating units were substantially as described in Example 9 below and as illustrated in
To assemble the thin film drug supply unit, the Nichrome wire comprising the initiator composition was positioned at one end of the solid fuel area. A bead of epoxy (Epo-Tek 353 ND, Epoxy Technology) was applied to both surfaces of the spacer, and the spacer, substrates and the ignition assembly positioned and compressed. The epoxy was cured at a temperature of 100° C. for 3 hours.
To ignite the solid fuel, a 0.4 amp current was applied to the electrical conductors connected to the Nichrome wire.
The peak internal pressure was measured using a pressure sensor (Motorola, MPXA4250A) The external surface temperature was measured using IR camera (FLIR, Therma CAM SC3000).
A solid fuel consisting of a mixture of zirconium (40.6 wt %), MoO3 (21.9 wt %), and KClO3 (1.9 wt %), nitrocellulose (0.6 wt %), and diatomaceous earth (35 wt %) was prepared. The solid fuel was placed in a 0.030-inch gap between a stainless steel substrate (0.015 inch wall thickness) and a stainless steel backing member (0.015 inch wall thickness). The diameter of the substrate was 9/16 inch. The fuel was ignited, and thermal images of the heating unit were taken as a function of time after ignition. The results are shown in
A. A solid fuel consisting of a mixture of zirconium (53.8 wt %), MoO3 (23.1 wt %), and KClO3 (2.3 wt %), nitrocellulose (0.8 wt %) and diatomaceous earth (20 wt %), was prepared. The solid fuel mixture was placed in a 0.030-inch gap between a stainless steel substrate (0.015 inch wall thickness) and a stainless steel backing member (0.015 inch wall thickness). The diameter of the substrate was 9/16 inch. The fuel was ignited, and a thermal image of the heating unit was taken 400 milliseconds after ignition. The image is shown in
B. A solid fuel consisting of a mixture of zirconium (46.9 wt %), MoO3 (25.2 wt %), KClO3 (2.2 wt %), nitrocellulose (0.7 wt %), and diatomaceous earth (25.0 wt %) was prepared. The solid fuel was placed in a 0.030-inch gap between a stainless steel substrate (0.015 inch wall thickness) and a stainless steel backing member (0.015 inch wall thickness). The diameter of the substrate was 9/16 inch. The fuel was ignited, and a thermal image of the heating unit was taken 400 milliseconds after ignition. The image is shown in
A solid fuel consisting of a mixture of zirconium (46.9 wt %), MoO3 (25.2 wt %), and KClO3 (2.2 wt %), grain size 100-325 mesh, along with nitrocellulose (0.7 wt %) and diatomaceous earth (25.0 wt %) was prepared. The solid fuel was placed in a 0.030-inch gap between a stainless steel substrate (0.015 inch wall thickness) and a stainless steel backing member (0.015 inch wall thickness). The diameter of the substrate was 9/16 inch. The solid fuel was remotely ignited from the tip of the heating unit. During and after burn, the pressure in the cylindrical substrate was measured as described herein. The burn propagation speed and the surface temperature uniformity were evaluated by infrared imaging.
The internal pressure increased to 150 psig during the reaction period of 0.3 seconds. The residual pressure was under 60 psig. The burn propagation speed was 13 cm/sec. With respect to surface temperature uniformity, no obvious cold spots were observed.
A solid fuel consisting of a mixture of zirconium (69.3 wt %) and MoO3 (29.7 wt %), grain size 100-325 mesh, along with nitrocellulose (1.0 wt %) was prepared. The solid fuel mixture was placed in a 0.020-inch gap between a stainless steel substrate (0.020 inch wall thickness) and a stainless steel backing member (0.020 inch wall thickness). The outside of the backing member was coated with initiator to increase burn propagation speed. The primary fuel was remotely ignited from the tip of the heating unit. During and after burn, the pressure in the cylindrical substrate was measured as described herein. The burn propagation speed and the surface temperature uniformity were evaluated by infrared imaging.
The internal pressure increased to 200 psig during the reaction period of 0.25 seconds. The residual pressure was under 60 psig. The burn propagation speed was 15 cm/sec. With respect to surface temperature uniformity, no obvious cold spots were observed.
A solid fuel consisting of a mixture of aluminum (49.5 wt %) and MoO3 (49.5 wt %), grain size 100-325 mesh, along with nitrocellulose (1.0 wt %) was prepared. The solid fuel mixture was placed in a 0.020-inch gap between a stainless steel substrate (0.020 inch wall thickness) and a stainless steel backing member (0.020 inch wall thickness). The primary fuel was directly ignited near the plug. During and after burn, the pressure in the cylindrical substrate was measured as described herein. The surface temperature uniformity was evaluated by infrared imaging.
The internal pressure increased to 300 psig during the reaction period of less than 5 milliseconds. The residual pressure was under 60 psig. The exterior surface expanse was uniformly heated, with between 5-10 percent of the surface being 50° C. to 100° C. cooler than the rest of the expanse.
The following procedure was used to prepare fuel compositions comprising Zr and MoO3 for a thin film drug supply unit. Wet Zr particles, 46.7 wt %, having a 2 μm to 3 μm particle size were obtained from Chemetall, GmbH, Germany. The Zr particles were rinsed with DI water, following which the excess water was decanted. DI water, 5.1 wt %, was added to the Zr and the mixture centrifuged. Excess water was decanted. Dry MoO3, 20 wt %, (Climax Molybdenum Co., AZ) and DI water was then added to the washed Zr, and the mixture homogenized for 2 minutes with a high shear mixer (IKA, Germany). A 15% aqueous solution of LAPONITE® RDS, 2.5 wt %, (Southern Clay Products, Inc., Texas) was added and the mixture homogenized with a high shear mixer for an additional 5 minutes. The Zr:MO3 solid fuel slurry was transferred to a syringe or holding vessel for subsequent coating. The wet Zr included 8.5 wt % water and the LAPONITE® RDS gel included 14 wt % water. The weight percents represent the percent weight of the total wet composition.
A thin film drug supply unit according to
To assemble the thin film drug supply unit, the Nichrome wire comprising the initiator composition was positioned at one end of the solid fuel area. A bead of epoxy (Epo-Tek 353 ND, Epoxy Technology) was applied to both surfaces of the spacer, and the spacer, substrates and the ignition assembly positioned and compressed. The epoxy was cured at a temperature of 100° C. for 3 hours.
To ignite the solid fuel, a 0.4 Amp current was applied to the electrical conductors connected to the Nichrome wire.
The airflow in the airway used for the measurements ranged from 14 L/min to 28 L/min corresponding to an airflow velocity of 1.5 m/sec and 3 n/sec, respectively.
Measurements on such drug supply units demonstrated that the exterior surface of the substrate reached temperatures in excess of 400° C. in less than 150 milliseconds following activation of the initiator at which time the drug was completely thermally vaporized. The maximum pressure within the enclosure was less than 10 psig. In separate measurements, it was demonstrated that the enclosure was able to withstand a static pressure in excess of 60 psig at room temperature. The burn propagation speed across the expanse of solid fuel was measured to be 25 cm/sec. The particulates forming the aerosol comprised greater than 95% of the drug, and greater than 90% of the drug originally deposited on the substrates formed the aerosol.
Drug supply units substantially as described in Example 9 and illustrated in
Two, 2×2 square inch, 0.004 inch thick 304 stainless steel foils formed the substrates. A solid fuel comprising 76.16 wt % Zr, 19.04% MoO3, 4.8% LAPONITE® RDS and water was coated onto the interior surface of the stainless steel substrates. The thickness of the solid fuel layer was 0.0018±0.0003 inches. The layer of solid fuel covered an area of 1.69 in2 and after drying, the weight of the solid fuel disposed on the interior surface of each substrate was 0.165 to 0.190 grams. An ˜6 μm thick thin film of a drug was deposited onto a 1.21 in2 area of the exterior substrate surfaces using spray coating. The drug was dissolved in a 15 mg/ml solution of isopropanol or acetone to facilitate processing. The thin film of drug was dried at ambient conditions and 1.5 mg to 3.0 mg of drug was deposited on the exterior surface of each substrate. The spacer comprised a 0.24 inch thick section of polycarbonate (Makronlon). The ignition assembly comprised a FR-4 printed circuit board having a 0.03 inch diameter opening at the end to be disposed within an enclosure defined by the spacer and the substrates. A 0.0008 inch diameter Nichrome wire was soldered to electrical conductors on the printed circuit board and positioned across the opening. An initiator composition comprising 26.5% Al, 51.4% MoO3, 7.7% B and 14.3% VITON® A500 weight percent was deposited onto the Nichrome wire and dried.
To assemble the thin film drug supply unit, the Nichrome wire comprising the initiator composition was positioned at one end of the solid fuel area. A bead of epoxy (Epo-Tek 353 ND, Epoxy Technology) was applied to both surfaces of the spacer, and the spacer, substrates and the ignition assembly positioned and compressed. The epoxy was cured at a temperature of 100° C. for 3 hours.
To ignite the solid fuel, a 0.4 Amp current was applied to the electrical conductors connected to the Nichrome wire.
The airflow in the airway used for the measurements ranged from 14 L/min to 28 L/min corresponding to an airflow velocity of 1.5 m/sec and 3 n/sec, respectively.
After volatilization, the aerosol was captured on a mat for quantification of yield and analysis of purity. The quantity of material recovered on the mat was used to determine a percent yield, based on the mass of drug coated onto the substrate. Any material deposited on the housing or the remaining on the substrate was also recovered and quantified to determine a percent total recovery ((mass of drug on the mat +mass of drug remaining on substrate and housing)/mass of drug coated onto substrate). For compounds without UV absorption GC/MS or LC/MS was used to quantify the recovery.
The percent purity was determined using HPLC UV absorption at 250 nm. However, as one of skill in the art recognizes, the purity of a drug-containing aerosol may be determined using a number of different methods. It should be noted that when the term “purity” is used, it refers to the percentage of aerosol minus the percent byproduct produced in its formation. Byproducts for example, are those unwanted products produced during vaporization. For example, byproducts include thermal degradation products as well as any unwanted metabolites of the active compound or compounds. Examples of suitable methods for determining aerosol purity are described in Sekine et al., Journal of Forensic Science 32:1271-1280 (1987) and in Martin et al., Journal of Analytic Toxicology 13:158-162 (1989).
One suitable method involves the use of a trap. In this method, the aerosol is collected in a trap in order to determine the percent or fraction of byproduct. Any suitable trap may be used. Suitable traps include mats, glass wool, impingers, solvent traps, cold traps, and the like. Mats are often most desirable. The trap is then typically extracted with a solvent, e.g. acetonitrile, and the extract subjected to analysis by any of a variety of analytical methods known in the art, for example, gas, liquid, and high performance liquid chromatography particularly useful.
The gas or liquid chromatography method typically includes a detector system, such as a mass spectrometry detector or an ultraviolet absorption detector. Ideally, the detector system allows determination of the quantity of the components of the drug composition and of the byproduct, by weight. This is achieved in practice by measuring the signal obtained upon analysis of one or more known mass(es) of components of the drug composition or byproduct (standards) and then comparing the signal obtained upon analysis of the aerosol to that obtained upon analysis of the standard(s), an approach well known in the art.
In many cases, the structure of a byproduct may not be known or a standard for it may not be available. In such cases, one may calculate the weight fraction of the byproduct by assuming it has an identical response coefficient (e.g. for ultraviolet absorption detection, identical extinction coefficient) to the drug component or components in the drug composition. When conducting such analysis, byproducts present in less than a very small fraction of the drug compound, e.g. less than 0.1% or 0.03% of the drug compound, are typically excluded. Because of the frequent necessity to assume an identical response coefficient between drug and byproduct in calculating a weight percentage of byproduct, it is often more desirable to use an analytical approach in which such an assumption has a high probability of validity. In this respect, high performance liquid chromatography with detection by absorption of ultraviolet light at 225 nm is typically desirable. UV absorption at 250 nm may be used for detection of compounds in cases where the compound absorbs more strongly at 250 nm or for other reasons one skilled in the art would consider detection at 250 nm the most appropriate means of estimating purity by weight using HPLC analysis. In certain cases where analysis of the drug by UV are not viable, other analytical tools such as GC/MS or LC/MS may be used to determine purity.
The following procedure was used to prepare solid fuel coatings comprising 76.16% Zr:19.04% MoO3:4.8% LAPONITE® RDS.
To prepare wet Zirconium (Zr), the as-obtained suspension of Zr in DI water (Chemetall, Germany) was agitated on a roto-mixer for 30 minutes. Ten to 40 mL of the wet Zr was dispensed into a 50 mL centrifuge tube and centrifuged (Sorvall 6200RT) for 30 minutes at 3,200 rpm. The DI water was removed to leave a wet Zr pellet.
To prepare a 15% LAPONITE® RDS solution, 85 grams of DI water was added to a beaker. While stirring, 15 grams of LAPONITE® RDS (Southern Clay Products, Gonzalez, Tex.) was added, and the suspension stirred for 30 minutes.
The reactant slurry was prepared by first removing the wet Zr pellet as previously prepared from the centrifuge tube and placed in a beaker. Upon weighing the wet Zr pellet, the weight of dry Zr was determined from the following equation: Dry Zr(g)=0.8234(Wet Zr(g))−0.1059.
The amount of molybdenum trioxide to provide a 80:20 ratio of Zr to MoO3 was then determined, e.g, MoO3=Dry Zr(g)/4, and the appropriate amount of MoO3 powder (Accumet, NY) was added to the beaker containing the wet Zr to produce a wet Zr: MoO3 slurry. The amount of LAPONITE® RDS to obtain a final weight percent ratio of dry components of 76.16% Zr:19.04% MoO3:4.80% LAPONITE® RDS was determined. Excess water to obtain a reactant slurry comprising 40% DI water was added to the wet Zr and MoO3 slurry. The reactant slurry was mixed for 5 minutes using an IKA Ultra-Turrax mixing motor with a S25N-8G dispersing head (setting 4). The amount of 15% LAPONITE® RDS previously determined was then added to the reactant slurry, and mixed for an additional 5 minutes using the IKA Ultra-Turrax mixer. The reactant slurry was transferred to a syringe and stored for at least 30 minutes prior to coating.
The Zr:MoO3:LAPONITE® RDS reactant slurry was then coated onto stainless steel foils. Stainless steel foils were first cleaned by sonication for 5 minutes in a 3.2% bv solution of Ridoline 298 in DI water at 60° C. Stainless steel foils were masked with 0.215 inch wide MYLAR® such that the center portion of each 0.004 inch thick 304 stainless steel foil was exposed. The foils were placed on a vacuum chuck having 0.008 inch thick shims at the edges. Two (2) mL of the reactant slurry was placed at one edge of the foil. Using a Sheen Auto-Draw Automatic Film Applicator 1137 (Sheen Instruments) the reactant slurry was coated onto the foils by drawing a #12 coating rod at an auto-draw coating speed of up to 50 mm/sec across the surface of the foils to deposit approximately an 0.006 inch thick layer of the Zr:MoO3:LAPONITE® RDS reactant slurry. The coated foils were then placed in a 40° C. forced-air convection oven and dried for at least 2 hours. The masks were then removed from the foils to leave a coating of solid fuel on the center section of each foil.
The ignition assembly comprised a thin stainless steel wire (wire anvil) dip coated ¼ an inch in an initiator composition comprising 620 parts by weight of titanium (size less than 20 μm), 100 part by weight of potassium chlorate, 180 parts by weight red phosphorus, 100 parts by weight sodium chlorate, and 620 parts by weight water with 2% polyvinyl alcohol binder. The coated wire was then dried at about 40-50° C. for 1 hour. The dried coated wire was placed into an ignition tube (soft walled aluminum tube 0.003 inch wall thickness) and one end was crimped to hold the wire in place.
To assemble the heating unit, the ignition tube was place between two fuel coated foil substrates (fuel chips) with the open end of the ignition tube aligned with the edge of the fuel coatings on the fuel chips. The fuel chips were sealed with aluminum adhesive tape.
To ignite the solid fuel, the ignition tube was struck with a brass rod. Both fuel chips in the heating unit readily ignited.
The following procedure was used to prepare solid fuel coatings comprising 76.16% Zr:19.04% MoO3:4.8% LAPONITE® RDS.
To prepare wet Zirconium (Zr), the as-obtained suspension of Zr in DI water (Chemetall, Germany) was agitated on a roto-mixer for 30 minutes.Ten to 40 mL of the wet Zr was dispensed into a 50 mL centrifuge tube and centrifuged (Sorvall 6200RT) for 30 minutes at 3,200 rpm. The DI water was removed to leave a wet Zr pellet.
To prepare a 15% LAPONITE® RDS solution, 85 grams of DI water was added to a beaker. While stirring, 15 grams of LAPONITE® RDS (Southern Clay Products, Gonzalez, Tex.) was added, and the suspension stirred for 30 minutes.
The reactant slurry was prepared by first removing the wet Zr pellet as previously prepared from the centrifuge tube and placed in a beaker. Upon weighing the wet Zr pellet, the weight of dry Zr was determined from the following equation: Dry Zr(g)=0.8234(Wet Zr(g))−0.1059.
The amount of molybdenum trioxide to provide a 80:20 ratio of Zr to MoO3 was then determined, e.g, MoO3=Dry Zr(g)/4, and the appropriate amount of MoO3 powder (Accumet, NY) was added to the beaker containing the wet Zr to produce a wet Zr:MoO3 slurry. The amount of LAPONITE® RDS to obtain a final weight percent ratio of dry components of 76.16% Zr:19.04% MoO3:4.80% LAPONITE® RDS was determined. Excess water to obtain a reactant slurry comprising 40% DI water was added to the wet Zr and MoO3 slurry. The reactant slurry was mixed for 5 minutes using an IKA Ultra-Turrax mixing motor with a S25N-8G dispersing head (setting 4). The amount of 15% LAPONITE® RDS previously determined was then added to the reactant slurry, and mixed for an additional 5 minutes using the IKA Ultra-Turrax mixer. The reactant slurry was transferred to a syringe and stored for at least 30 minutes prior to coating.
The Zr:MoO3:LAPONITE® RDS reactant slurry was then coated onto 3 inch circular stainless steel foils. Stainless steel foils were first cleaned by sonication for 5 minutes in a 3.2% by solution of Ridoline 298 in DI water at 60° C. Stainless steel foils 91 were masked with a 3 inch round sheet of MYLAR® with twelve 0.25 inch by 0.5 inch spaces cut into the MYLAR® so that twelve rectangles of 0.25 by 0.5 inches of 0.004 inch thick 304 stainless steel foil was exposed. The foils were placed on a vacuum chuck having 0.008 inch thick shims at the edges. Two (2) mL of the reactant slurry was placed at one edge of the foil. Using a Sheen Auto-Draw Automatic Film Applicator 1137 (Sheen Instruments) the reactant slurry was coated onto the foils by drawing a #12 coating rod at an auto-draw coating speed of up to 50 mm/sec across the surface of the foils to deposit approximately an 0.006 inch thick layer of the Zr:MoO3:LAPONITE® RDS reactant slurry. The coated foils were then placed in a 40° C. forced-air convection oven and dried for at least 2 hours. The masks were then removed from the foils to leave twelve rectangular coatings of solid fuel on each foil.
An initiator composition was prepared by adding 8.6 mL of a 4.25% VITON® A500/amyl acetate solution to a mixture of 0.680 g of Al (40-70 nm), 1.320 g of MoO3 (nano), and 0.200 g of boron (nano) and mixing well. Two 1 iL drops of the initiator composition were placed in a 0.06 inch diameter hole in the center of each of twelve 0.25 inch by 0.5 inch fiberglass mats (.04 inch thickness, Directed Light). One drop of initiator composition was place in the hole from each side of fiberglass mat.
To assemble the heating unit, on the fuel coated foil (3 inch diameter) was placed four layers of double sided tape (3 inch diameter, Saint-Gobain Performance Plastics) with 12 rectangular holes (0.25 inch by 0.5 inch) cut into each tape such that the holes on the tape aligned with the fuel coatings on the foils. Into each hole in the tape layer was placed one fiberglass mat with the initiator. The tape was then covered with a 3 inch circular window made out of clear plastic ( 1/16 inch polycarbonate sheet, McMaster-Carr).
Each heating unit of the device was ignited is succession by pulsed flash light from a Xenon lamp powered by one AA battery through the polycarbonate window.
Although the invention has been described with respect to particular embodiments, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the invention.
This application is a continuation-in-part of U.S. application Ser. No. 10/850,895 filed May 20, 2004 and is a continuation-in-part of U.S. application Ser. No. 10/851,429 filed May 20, 2004 and is a continuation-in-part of U.S. application Ser. No. 10/851,883 filed May 20, 2004 and is a continuation-in-part of U.S. application Ser. No. 10/851,432 filed May 20, 2004. These applications claim priority to U.S. provisional application Ser. No. 60/472,697 entitled “Self-Contained Heating Unit and Drug-Supply Unit Employing Same,” filed May 21, 2003, Hale et al. The entire disclosures of which are hereby incorporated by reference. Any disclaimer that may have occurred during the prosecution of the above-referenced applications is hereby expressly rescinded, and reconsideration of all relevant art is respectfully requested.
This invention was made with Government support under Grant No. R44 NS044800, awarded by the National Institutes of Health. The Government has certain rights in the invention.
| Number | Name | Date | Kind |
|---|---|---|---|
| 802256 | Bamberger et al. | Oct 1905 | A |
| 1239634 | Stuart | Sep 1917 | A |
| 1535486 | Lundy | Apr 1925 | A |
| 1803334 | Lehmann | May 1931 | A |
| 1864980 | Curran | Jun 1932 | A |
| 2024225 | Igari | Dec 1935 | A |
| 2084299 | Borden | Jun 1937 | A |
| 2086140 | Ernst | Jul 1937 | A |
| 2230753 | Klavehn et al. | Feb 1941 | A |
| 2230754 | Klavehn et al. | Feb 1941 | A |
| 2243669 | Clyne | May 1941 | A |
| 2280598 | Meridith | Apr 1942 | A |
| 2309846 | Holm | Feb 1943 | A |
| 2469656 | Lienert | May 1949 | A |
| 2491416 | Olson et al. | Dec 1949 | A |
| 2500790 | Bennett | Mar 1950 | A |
| 2531548 | Bennett | Nov 1950 | A |
| 2598823 | O'Grady et al. | Jun 1952 | A |
| 2624332 | Lang | Jan 1953 | A |
| 2714649 | Critzer | Aug 1955 | A |
| 2741812 | Andre | Apr 1956 | A |
| 2761055 | Ike | Aug 1956 | A |
| 2887106 | Robinson | May 1959 | A |
| 2898649 | Murray | Aug 1959 | A |
| 2902484 | Horclois | Sep 1959 | A |
| 2906094 | Damon et al. | Sep 1959 | A |
| 2953443 | Lloyd | Sep 1960 | A |
| 2999460 | Stinger et al. | Sep 1961 | A |
| 3043977 | Morowitz | Jul 1962 | A |
| 3080624 | Webber, III | Mar 1963 | A |
| 3118798 | Winkler | Jan 1964 | A |
| 3150020 | Kilmer | Sep 1964 | A |
| 3160097 | Colburn, Jr. et al. | Dec 1964 | A |
| 3164600 | Janssen et al. | Jan 1965 | A |
| 3169095 | Thiel et al. | Feb 1965 | A |
| 3200819 | Gilbert | Aug 1965 | A |
| 3219533 | Mullins | Nov 1965 | A |
| 3238076 | Taylor et al. | Mar 1966 | A |
| 3282729 | Richardson et al. | Nov 1966 | A |
| 3296249 | Bell | Jan 1967 | A |
| 3299185 | Oda et al. | Jan 1967 | A |
| 3311459 | Francis et al. | Mar 1967 | A |
| 3363559 | Estes | Jan 1968 | A |
| 3371085 | Reeder et al. | Feb 1968 | A |
| 3393197 | Pachter | Jul 1968 | A |
| 3433791 | Bentley et al. | Mar 1969 | A |
| 3503814 | Helms, Jr. et al. | Mar 1970 | A |
| 3535063 | Anderson et al. | Oct 1970 | A |
| 3560607 | Hartley et al. | Feb 1971 | A |
| 3575714 | Bennett et al. | Apr 1971 | A |
| 3580250 | Oroza | May 1971 | A |
| 3695179 | Rainone et al. | Oct 1972 | A |
| 3701782 | Hester | Oct 1972 | A |
| 3703144 | Colburn, Jr. | Nov 1972 | A |
| 3724990 | Schupp | Apr 1973 | A |
| 3724991 | Schupp | Apr 1973 | A |
| 3730669 | Shaffer | May 1973 | A |
| 3749547 | Gregory et al. | Jul 1973 | A |
| 3763347 | Whitaker et al. | Oct 1973 | A |
| 3791302 | McLeod | Feb 1974 | A |
| 3792302 | Downing et al. | Feb 1974 | A |
| 3828676 | Junker | Aug 1974 | A |
| 3830671 | McArdle | Aug 1974 | A |
| 3831606 | Damani | Aug 1974 | A |
| 3847650 | Gregory et al. | Nov 1974 | A |
| 3864326 | Babington | Feb 1975 | A |
| 3893798 | Sterling | Jul 1975 | A |
| 3894040 | Buzby, Jr. | Jul 1975 | A |
| 3909463 | Hartman | Sep 1975 | A |
| 3930796 | Haensel | Jan 1976 | A |
| 3943941 | Boyd et al. | Mar 1976 | A |
| 3949743 | Shanbrom | Apr 1976 | A |
| 3971377 | Damani | Jul 1976 | A |
| 3982095 | Robinson | Sep 1976 | A |
| 3987052 | Hester, Jr. | Oct 1976 | A |
| 4000022 | Beckert et al. | Dec 1976 | A |
| 4008723 | Borthwick et al. | Feb 1977 | A |
| 4013061 | Trumble et al. | Mar 1977 | A |
| 4020379 | Manning | Apr 1977 | A |
| 4025285 | Brown | May 1977 | A |
| 4045156 | Chu et al. | Aug 1977 | A |
| 4047483 | Williams | Sep 1977 | A |
| 4053337 | Collins | Oct 1977 | A |
| 4059388 | Shaffer | Nov 1977 | A |
| 4078881 | Anderson et al. | Mar 1978 | A |
| 4079742 | Rainer et al. | Mar 1978 | A |
| 4096549 | Anderson et al. | Jun 1978 | A |
| 4104210 | Coran et al. | Aug 1978 | A |
| 4121583 | Chen | Oct 1978 | A |
| 4130082 | Bouchard et al. | Dec 1978 | A |
| 4141369 | Burruss | Feb 1979 | A |
| 4158084 | Prentice | Jun 1979 | A |
| 4160765 | Weinstock | Jul 1979 | A |
| 4166087 | Cline et al. | Aug 1979 | A |
| 4183912 | Rosenthale | Jan 1980 | A |
| 4184099 | Lindauer et al. | Jan 1980 | A |
| 4190654 | Gherardi et al. | Feb 1980 | A |
| 4193388 | Yang | Mar 1980 | A |
| 4198200 | Fonda et al. | Apr 1980 | A |
| RE30285 | Babington | May 1980 | E |
| 4205673 | Wise | Jun 1980 | A |
| 4219031 | Rainer et al. | Aug 1980 | A |
| 4229447 | Porter | Oct 1980 | A |
| 4229931 | Schlueter et al. | Oct 1980 | A |
| 4232002 | Nogrady | Nov 1980 | A |
| 4236544 | Osaka | Dec 1980 | A |
| 4251525 | Weinstock | Feb 1981 | A |
| 4276243 | Partus | Jun 1981 | A |
| 4280629 | Slaughter | Jul 1981 | A |
| 4284089 | Ray | Aug 1981 | A |
| 4286604 | Ehretsmann et al. | Sep 1981 | A |
| 4303083 | Burruss, Jr. | Dec 1981 | A |
| 4329924 | Lagofun | May 1982 | A |
| 4340072 | Bolt et al. | Jul 1982 | A |
| 4346059 | Spector | Aug 1982 | A |
| 4347855 | Lanzillotti et al. | Sep 1982 | A |
| 4354432 | Cannavo et al. | Oct 1982 | A |
| 4372210 | Shaffer et al. | Feb 1983 | A |
| 4372213 | Rozner et al. | Feb 1983 | A |
| 4374686 | Davitt et al. | Feb 1983 | A |
| 4376767 | Sloan | Mar 1983 | A |
| 4391285 | Burnett et al. | Jul 1983 | A |
| 4419153 | Boberg | Dec 1983 | A |
| 4423071 | Chignac et al. | Dec 1983 | A |
| 4474191 | Steiner | Oct 1984 | A |
| 4484576 | Albarda | Nov 1984 | A |
| 4484960 | Rucker | Nov 1984 | A |
| 4508726 | Coleman | Apr 1985 | A |
| 4523589 | Krauser | Jun 1985 | A |
| 4526758 | Alengoz et al. | Jul 1985 | A |
| 4556539 | Spector | Dec 1985 | A |
| 4566451 | Badewien | Jan 1986 | A |
| 4588425 | Usry et al. | May 1986 | A |
| 4588721 | Mahan | May 1986 | A |
| 4591615 | Aldred et al. | May 1986 | A |
| 4605552 | Fritschi | Aug 1986 | A |
| 4627963 | Olson | Dec 1986 | A |
| 4647428 | Gyulay | Mar 1987 | A |
| 4647433 | Spector | Mar 1987 | A |
| 4654370 | Marriott, III et al. | Mar 1987 | A |
| 4671270 | Kato | Jun 1987 | A |
| 4683231 | Glassman | Jul 1987 | A |
| 4693868 | Katsuda et al. | Sep 1987 | A |
| 4700629 | Benson et al. | Oct 1987 | A |
| 4708151 | Shelar | Nov 1987 | A |
| 4714082 | Banerjee et al. | Dec 1987 | A |
| 4721224 | Kawabata | Jan 1988 | A |
| 4722334 | Blackmer et al. | Feb 1988 | A |
| 4734560 | Bowen | Mar 1988 | A |
| 4735217 | Gerth et al. | Apr 1988 | A |
| 4735358 | Morita et al. | Apr 1988 | A |
| 4753758 | Miller | Jun 1988 | A |
| 4755508 | Bock et al. | Jul 1988 | A |
| 4756318 | Clearman et al. | Jul 1988 | A |
| 4757764 | Thureson et al. | Jul 1988 | A |
| 4765347 | Sensabaugh, Jr. et al. | Aug 1988 | A |
| 4771795 | White et al. | Sep 1988 | A |
| 4774971 | Vieten | Oct 1988 | A |
| 4793365 | Sensabaugh, Jr. et al. | Dec 1988 | A |
| 4793366 | Hill | Dec 1988 | A |
| 4800903 | Ray et al. | Jan 1989 | A |
| 4801411 | Wellinghoff et al. | Jan 1989 | A |
| 4814161 | Jinks et al. | Mar 1989 | A |
| 4819665 | Roberts et al. | Apr 1989 | A |
| 4848374 | Chard et al. | Jul 1989 | A |
| 4852561 | Sperry | Aug 1989 | A |
| 4853052 | Calsson et al. | Aug 1989 | A |
| 4853517 | Bowen et al. | Aug 1989 | A |
| 4854331 | Banerjee et al. | Aug 1989 | A |
| 4858630 | Banerjee et al. | Aug 1989 | A |
| 4863720 | Burghart et al. | Sep 1989 | A |
| 4881541 | Eger et al. | Nov 1989 | A |
| 4881556 | Clearman et al. | Nov 1989 | A |
| 4889850 | Thornfeldt et al. | Dec 1989 | A |
| 4892037 | Betts | Jan 1990 | A |
| 4892109 | Strubel | Jan 1990 | A |
| 4895719 | Radhakrishnun et al. | Jan 1990 | A |
| 4906417 | Gentry | Mar 1990 | A |
| 4911157 | Miller | Mar 1990 | A |
| 4917119 | Potter et al. | Apr 1990 | A |
| 4917120 | Hill | Apr 1990 | A |
| 4917830 | Ortiz et al. | Apr 1990 | A |
| 4922901 | Brooks et al. | May 1990 | A |
| 4924883 | Perfetti et al. | May 1990 | A |
| 4928714 | Shannon | May 1990 | A |
| 4941483 | Ridings et al. | Jul 1990 | A |
| 4947874 | Brooks et al. | Aug 1990 | A |
| 4947875 | Brooks et al. | Aug 1990 | A |
| 4963289 | Ortiz et al. | Oct 1990 | A |
| 4984158 | Hillsman | Jan 1991 | A |
| 4989619 | Clearman et al. | Feb 1991 | A |
| 5016425 | Weick | May 1991 | A |
| 5017575 | Golwyn | May 1991 | A |
| 5019122 | Clearman et al. | May 1991 | A |
| 5020548 | Farrier et al. | Jun 1991 | A |
| 5027707 | Mei | Jul 1991 | A |
| 5027836 | Shannon et al. | Jul 1991 | A |
| 5033483 | Clearman et al. | Jul 1991 | A |
| 5042509 | Banerjee et al. | Aug 1991 | A |
| 5049389 | Radhakrishnun | Sep 1991 | A |
| 5060666 | Clearman et al. | Oct 1991 | A |
| 5060667 | Strubel | Oct 1991 | A |
| 5060671 | Counts et al. | Oct 1991 | A |
| 5067499 | Banerjee et al. | Nov 1991 | A |
| 5072726 | Mazloomdoost et al. | Dec 1991 | A |
| 5076292 | Sensabaugh, Jr. et al. | Dec 1991 | A |
| 5099861 | Clearman et al. | Mar 1992 | A |
| 5109180 | Boultinghouse et al. | Apr 1992 | A |
| 5112598 | Biesalski | May 1992 | A |
| 5118494 | Schultz et al. | Jun 1992 | A |
| 5119834 | Shannon et al. | Jun 1992 | A |
| 5126123 | Johnson | Jun 1992 | A |
| 5133368 | Neumann et al. | Jul 1992 | A |
| 5135009 | Muller et al. | Aug 1992 | A |
| 5137034 | Perfetti et al. | Aug 1992 | A |
| 5144962 | Counts et al. | Sep 1992 | A |
| 5146915 | Montgomery | Sep 1992 | A |
| 5156170 | Clearman et al. | Oct 1992 | A |
| 5160664 | Liu | Nov 1992 | A |
| 5164740 | Ivri | Nov 1992 | A |
| 5166202 | Schweizer | Nov 1992 | A |
| 5167242 | Turner et al. | Dec 1992 | A |
| 5177071 | Freidinger et al. | Jan 1993 | A |
| 5186164 | Raghuprasad | Feb 1993 | A |
| 5192548 | Velasquez et al. | Mar 1993 | A |
| 5224498 | Deevi et al. | Jul 1993 | A |
| 5229120 | DeVincent | Jul 1993 | A |
| 5229382 | Chakrabarti et al. | Jul 1993 | A |
| 5240922 | O'Neill | Aug 1993 | A |
| 5249586 | Morgan et al. | Oct 1993 | A |
| 5255674 | Oftedal et al. | Oct 1993 | A |
| 5261424 | Sprinkel, Jr. | Nov 1993 | A |
| 5264433 | Sato et al. | Nov 1993 | A |
| 5284133 | Burns et al. | Feb 1994 | A |
| 5285798 | Banerjee et al. | Feb 1994 | A |
| 5292499 | Evans et al. | Mar 1994 | A |
| 5322018 | Hadden et al. | Jun 1994 | A |
| 5322075 | Deevi et al. | Jun 1994 | A |
| 5333106 | Lanpher et al. | Jul 1994 | A |
| 5345951 | Serrano et al. | Sep 1994 | A |
| 5357984 | Farrier et al. | Oct 1994 | A |
| 5363842 | Mishelevich et al. | Nov 1994 | A |
| 5364838 | Rubsamen | Nov 1994 | A |
| 5366770 | Wang | Nov 1994 | A |
| 5372148 | McCafferty et al. | Dec 1994 | A |
| 5376386 | Ganderton et al. | Dec 1994 | A |
| 5388574 | Ingebrethsen | Feb 1995 | A |
| 5391081 | Lampotang et al. | Feb 1995 | A |
| 5399574 | Robertson et al. | Mar 1995 | A |
| 5400808 | Turner et al. | Mar 1995 | A |
| 5431167 | Savord | Jul 1995 | A |
| 5436230 | Soudant et al. | Jul 1995 | A |
| 5445606 | Haak et al. | Aug 1995 | A |
| 5451408 | Mezei et al. | Sep 1995 | A |
| 5454363 | Sata | Oct 1995 | A |
| 5456247 | Shilling et al. | Oct 1995 | A |
| 5456677 | Spector | Oct 1995 | A |
| 5457100 | Daniel | Oct 1995 | A |
| 5457101 | Greenwood et al. | Oct 1995 | A |
| 5459137 | Andrasi et al. | Oct 1995 | A |
| 5462740 | Evenstad et al. | Oct 1995 | A |
| 5468936 | Deevi et al. | Nov 1995 | A |
| 5479919 | Buchtal | Jan 1996 | A |
| 5501236 | Hill et al. | Mar 1996 | A |
| 5507277 | Rubsamen et al. | Apr 1996 | A |
| 5509354 | Dorffler et al. | Apr 1996 | A |
| 5511726 | Greenspan et al. | Apr 1996 | A |
| 5519019 | Andrasi et al. | May 1996 | A |
| 5522385 | Lloyd et al. | Jun 1996 | A |
| 5525329 | Snyder et al. | Jun 1996 | A |
| 5538020 | Farrier et al. | Jul 1996 | A |
| 5543434 | Weg | Aug 1996 | A |
| 5544646 | Lloyd et al. | Aug 1996 | A |
| 5549849 | Namura et al. | Aug 1996 | A |
| 5564442 | MacDonald et al. | Oct 1996 | A |
| 5573565 | Dalton et al. | Nov 1996 | A |
| 5584701 | Lampotang et al. | Dec 1996 | A |
| 5586550 | Ivri et al. | Dec 1996 | A |
| 5591368 | Fleischhauer et al. | Jan 1997 | A |
| 5592934 | Thwaites | Jan 1997 | A |
| 5593792 | Farrier et al. | Jan 1997 | A |
| 5605146 | Sarela | Feb 1997 | A |
| 5605897 | Beasley, Jr. et al. | Feb 1997 | A |
| 5607691 | Hale et al. | Mar 1997 | A |
| 5619984 | Hodson et al. | Apr 1997 | A |
| 5622944 | Hale et al. | Apr 1997 | A |
| 5623115 | Lauritzen et al. | Apr 1997 | A |
| 5626360 | Lauritzen et al. | May 1997 | A |
| 5627178 | Chakrabarti et al. | May 1997 | A |
| 5641938 | Holland et al. | Jun 1997 | A |
| 5649554 | Sprinkel | Jul 1997 | A |
| 5654520 | Boberg et al. | Aug 1997 | A |
| 5655523 | Hodson et al. | Aug 1997 | A |
| 5656255 | Jones | Aug 1997 | A |
| 5660166 | Lloyd et al. | Aug 1997 | A |
| 5660413 | Bergerson et al. | Aug 1997 | A |
| 5666977 | Higgins et al. | Sep 1997 | A |
| 5672843 | Evans et al. | Sep 1997 | A |
| 5686691 | Hamilton et al. | Nov 1997 | A |
| 5690809 | Subramaniam et al. | Nov 1997 | A |
| 5694919 | Rubsamen et al. | Dec 1997 | A |
| 5697896 | McNichols et al. | Dec 1997 | A |
| 5718222 | Lloyd et al. | Feb 1998 | A |
| 5724957 | Rubsamen et al. | Mar 1998 | A |
| 5725756 | Subramaniam et al. | Mar 1998 | A |
| 5733572 | Unger et al. | Mar 1998 | A |
| 5735263 | Rubsamen et al. | Apr 1998 | A |
| 5738865 | Baichwal et al. | Apr 1998 | A |
| 5743250 | Gonda et al. | Apr 1998 | A |
| 5743251 | Howell et al. | Apr 1998 | A |
| 5744469 | Tran | Apr 1998 | A |
| 5747001 | Wiedmann et al. | May 1998 | A |
| 5756449 | Andersen et al. | May 1998 | A |
| 5758637 | Ivri et al. | Jun 1998 | A |
| 5763813 | Cohen et al. | Jun 1998 | A |
| 5767117 | Moskowitz et al. | Jun 1998 | A |
| 5769621 | Early et al. | Jun 1998 | A |
| 5770222 | Unger et al. | Jun 1998 | A |
| 5771882 | Psaros et al. | Jun 1998 | A |
| 5776928 | Beasley, Jr. | Jul 1998 | A |
| 5804212 | Illum | Sep 1998 | A |
| 5809997 | Wolf | Sep 1998 | A |
| 5817656 | Beasley, Jr. et al. | Oct 1998 | A |
| 5819756 | Mielordt | Oct 1998 | A |
| 5823178 | Lloyd et al. | Oct 1998 | A |
| 5829436 | Rubsamen et al. | Nov 1998 | A |
| 5833891 | Subramaniam et al. | Nov 1998 | A |
| 5840246 | Hammons et al. | Nov 1998 | A |
| 5845933 | Walker et al. | Dec 1998 | A |
| 5855564 | Ruskewicz | Jan 1999 | A |
| 5855913 | Hanes et al. | Jan 1999 | A |
| 5874064 | Edwards et al. | Feb 1999 | A |
| 5874481 | Weers et al. | Feb 1999 | A |
| 5875776 | Vaghefi | Mar 1999 | A |
| 5878752 | Adams et al. | Mar 1999 | A |
| 5884620 | Gonda et al. | Mar 1999 | A |
| 5890908 | Lampotang et al. | Apr 1999 | A |
| 5894841 | Voges | Apr 1999 | A |
| 5900249 | Smith | May 1999 | A |
| 5906811 | Hersh | May 1999 | A |
| 5907075 | Subramaniam et al. | May 1999 | A |
| 5910301 | Farr et al. | Jun 1999 | A |
| 5915378 | Lloyd et al. | Jun 1999 | A |
| 5918595 | Olsson | Jul 1999 | A |
| 5928520 | Haumesser | Jul 1999 | A |
| 5929093 | Pang et al. | Jul 1999 | A |
| 5934272 | Lloyd et al. | Aug 1999 | A |
| 5934289 | Watkins et al. | Aug 1999 | A |
| 5935604 | Illum | Aug 1999 | A |
| 5938117 | Ivri | Aug 1999 | A |
| 5939100 | Albrechtsen et al. | Aug 1999 | A |
| 5941240 | Gonda et al. | Aug 1999 | A |
| 5944012 | Pera | Aug 1999 | A |
| 5957124 | Lloyd et al. | Sep 1999 | A |
| 5960792 | Lloyd et al. | Oct 1999 | A |
| 5970973 | Gonda et al. | Oct 1999 | A |
| 5971951 | Ruskewicz | Oct 1999 | A |
| 5985309 | Edwards et al. | Nov 1999 | A |
| 5993805 | Sutton et al. | Nov 1999 | A |
| 6004970 | O'Malley et al. | Dec 1999 | A |
| 6008214 | Kwon et al. | Dec 1999 | A |
| 6008216 | Chakrabarti et al. | Dec 1999 | A |
| 6013050 | Bellhouse et al. | Jan 2000 | A |
| 6014969 | Lloyd et al. | Jan 2000 | A |
| 6014970 | Ivri et al. | Jan 2000 | A |
| 6014972 | Sladek | Jan 2000 | A |
| 6041777 | Faithfull et al. | Mar 2000 | A |
| 6044777 | Walsh | Apr 2000 | A |
| 6048550 | Chan et al. | Apr 2000 | A |
| 6048857 | Ellinwood, Jr. et al. | Apr 2000 | A |
| 6050260 | Daniell et al. | Apr 2000 | A |
| 6051257 | Kodas et al. | Apr 2000 | A |
| 6051566 | Bianco | Apr 2000 | A |
| 6062210 | Welles | May 2000 | A |
| RE36744 | Goldberg | Jun 2000 | E |
| 6080248 | Finck et al. | Jun 2000 | A |
| 6089857 | Matsuura et al. | Jul 2000 | A |
| 6090212 | Mahawili | Jul 2000 | A |
| 6095134 | Sievers et al. | Aug 2000 | A |
| 6095153 | Kessler et al. | Aug 2000 | A |
| 6098619 | Britto et al. | Aug 2000 | A |
| 6102036 | Slutsky et al. | Aug 2000 | A |
| 6113795 | Subramaniam et al. | Sep 2000 | A |
| 6117866 | Bondinell et al. | Sep 2000 | A |
| 6125853 | Susa et al. | Oct 2000 | A |
| 6126919 | Stefely et al. | Oct 2000 | A |
| 6131566 | Ashurst et al. | Oct 2000 | A |
| 6131570 | Schuster et al. | Oct 2000 | A |
| 6133327 | Kimura et al. | Oct 2000 | A |
| 6135369 | Prendergast et al. | Oct 2000 | A |
| 6155268 | Takeuchi | Dec 2000 | A |
| 6168661 | Dinkelman | Jan 2001 | B1 |
| 6211171 | Sawynok et al. | Apr 2001 | B1 |
| 6234167 | Cox et al. | May 2001 | B1 |
| 6241969 | Saidi et al. | Jun 2001 | B1 |
| 6250301 | Pate | Jun 2001 | B1 |
| 6255334 | Sands | Jul 2001 | B1 |
| 6263872 | Schuster et al. | Jul 2001 | B1 |
| 6264922 | Wood et al. | Jul 2001 | B1 |
| 6267110 | Tenenboum et al. | Jul 2001 | B1 |
| 6284287 | Sarlikiotis et al. | Sep 2001 | B1 |
| 6289813 | Duguet et al. | Sep 2001 | B1 |
| 6289889 | Bell et al. | Sep 2001 | B1 |
| 6290986 | Murdock et al. | Sep 2001 | B1 |
| 6299900 | Reed et al. | Oct 2001 | B1 |
| 6300710 | Nakamori | Oct 2001 | B1 |
| 6306431 | Zhang et al. | Oct 2001 | B1 |
| 6313176 | Ellinwood, Jr. et al. | Nov 2001 | B1 |
| 6324979 | Troianello | Dec 2001 | B1 |
| 6352506 | Eppstein et al. | Mar 2002 | B1 |
| 6376550 | Raber et al. | Apr 2002 | B1 |
| 6391282 | Dugger, III | May 2002 | B1 |
| 6408854 | Gonda et al. | Jun 2002 | B1 |
| 6413930 | Ratti et al. | Jul 2002 | B1 |
| 6420351 | Tsai et al. | Jul 2002 | B1 |
| 6431166 | Gonda et al. | Aug 2002 | B2 |
| 6443152 | Lockhart et al. | Sep 2002 | B1 |
| 6444326 | Smith | Sep 2002 | B1 |
| 6444665 | Helton et al. | Sep 2002 | B1 |
| 6461591 | Keller et al. | Oct 2002 | B1 |
| 6478903 | John, Jr. et al. | Nov 2002 | B1 |
| 6479074 | Murdock et al. | Nov 2002 | B2 |
| 6487971 | Anderson | Dec 2002 | B1 |
| 6491233 | Nichols | Dec 2002 | B2 |
| 6497780 | Carlson | Dec 2002 | B1 |
| 6506454 | Ishigami | Jan 2003 | B2 |
| 6506762 | Horvath et al. | Jan 2003 | B1 |
| 6514482 | Bartus et al. | Feb 2003 | B1 |
| 6516796 | Cox et al. | Feb 2003 | B1 |
| 6557552 | Cox et al. | May 2003 | B1 |
| 6568390 | Nichols et al. | May 2003 | B2 |
| 6591839 | Meyer et al. | Jul 2003 | B2 |
| 6632047 | Vinegar et al. | Oct 2003 | B2 |
| 6638981 | Williams et al. | Oct 2003 | B2 |
| 6682716 | Hodges et al. | Jan 2004 | B2 |
| 6701922 | Hindle et al. | Mar 2004 | B2 |
| 6716415 | Rabinowitz et al. | Apr 2004 | B2 |
| 6716416 | Rabinowitz et al. | Apr 2004 | B2 |
| 6716417 | Rabinowitz et al. | Apr 2004 | B2 |
| 6737042 | Rabinowitz et al. | May 2004 | B2 |
| 6737043 | Rabinowitz et al. | May 2004 | B2 |
| 6740307 | Rabinowitz et al. | May 2004 | B2 |
| 6740308 | Rabinowitz et al. | May 2004 | B2 |
| 6740309 | Rabinowitz et al. | May 2004 | B2 |
| 6743415 | Rabinowitz et al. | Jun 2004 | B2 |
| 6759029 | Hale et al. | Jul 2004 | B2 |
| 6772756 | Shayan | Aug 2004 | B2 |
| 6772757 | Sprinkel, Jr. et al. | Aug 2004 | B2 |
| 6776978 | Rabinowitz et al. | Aug 2004 | B2 |
| 6779520 | Genova et al. | Aug 2004 | B2 |
| 6780399 | Rabinowitz et al. | Aug 2004 | B2 |
| 6780400 | Rabinowitz et al. | Aug 2004 | B2 |
| 6783753 | Rabinowitz et al. | Aug 2004 | B2 |
| 6797259 | Rabinowitz et al. | Sep 2004 | B2 |
| 6803031 | Rabinowitz et al. | Oct 2004 | B2 |
| 6805853 | Rabinowitz et al. | Oct 2004 | B2 |
| 6805854 | Hale et al. | Oct 2004 | B2 |
| 6814954 | Rabinowitz et al. | Nov 2004 | B2 |
| 6814955 | Rabinowitz et al. | Nov 2004 | B2 |
| 6855310 | Rabinowitz et al. | Feb 2005 | B2 |
| 6884408 | Rabinowitz et al. | Apr 2005 | B2 |
| 6993811 | Das et al. | Feb 2006 | B2 |
| 6994843 | Rabinowitz et al. | Feb 2006 | B2 |
| 7005121 | Rabinowitz et al. | Feb 2006 | B2 |
| 7005122 | Hale et al. | Feb 2006 | B2 |
| 7008615 | Rabinowitz et al. | Mar 2006 | B2 |
| 7008616 | Rabinowitz et al. | Mar 2006 | B2 |
| 7011819 | Hale et al. | Mar 2006 | B2 |
| 7011820 | Rabinowitz et al. | Mar 2006 | B2 |
| 7014840 | Hale et al. | Mar 2006 | B2 |
| 7014841 | Rabinowitz et al. | Mar 2006 | B2 |
| 7018619 | Rabinowitz et al. | Mar 2006 | B2 |
| 7018620 | Rabinowitz et al. | Mar 2006 | B2 |
| 7018621 | Hale et al. | Mar 2006 | B2 |
| 7022312 | Rabinowitz et al. | Apr 2006 | B2 |
| 7029658 | Rabinowitz et al. | Apr 2006 | B2 |
| 7033575 | Rabinowitz et al. | Apr 2006 | B2 |
| 7040314 | Nguyen et al. | May 2006 | B2 |
| 7045118 | Rabinowitz et al. | May 2006 | B2 |
| 7045119 | Rabinowitz et al. | May 2006 | B2 |
| 7048909 | Rabinowitz et al. | May 2006 | B2 |
| 7052679 | Rabinowitz et al. | May 2006 | B2 |
| 7052680 | Rabinowitz et al. | May 2006 | B2 |
| 7060254 | Rabinowitz et al. | Jun 2006 | B2 |
| 7060255 | Rabinowitz et al. | Jun 2006 | B2 |
| 7063830 | Rabinowitz et al. | Jun 2006 | B2 |
| 7063831 | Rabinowitz et al. | Jun 2006 | B2 |
| 7063832 | Rabinowitz et al. | Jun 2006 | B2 |
| 7067114 | Rabinowitz et al. | Jun 2006 | B2 |
| 7070761 | Rabinowitz et al. | Jul 2006 | B2 |
| 7070762 | Rabinowitz et al. | Jul 2006 | B2 |
| 7070763 | Rabinowitz et al. | Jul 2006 | B2 |
| 7070764 | Rabinowitz et al. | Jul 2006 | B2 |
| 7070765 | Rabinowitz et al. | Jul 2006 | B2 |
| 7070766 | Rabinowitz et al. | Jul 2006 | B2 |
| 7078016 | Rabinowitz et al. | Jul 2006 | B2 |
| 7078017 | Rabinowitz et al. | Jul 2006 | B2 |
| 7078018 | Rabinowitz et al. | Jul 2006 | B2 |
| 7078019 | Rabinowitz et al. | Jul 2006 | B2 |
| 7078020 | Rabinowitz et al. | Jul 2006 | B2 |
| 7087216 | Rabinowitz et al. | Aug 2006 | B2 |
| 7087217 | Rabinowitz et al. | Aug 2006 | B2 |
| 7087218 | Rabinowitz et al. | Aug 2006 | B2 |
| 7090830 | Hale et al. | Aug 2006 | B2 |
| 7094392 | Rabinowitz et al. | Aug 2006 | B2 |
| 7108847 | Rabinowitz et al. | Sep 2006 | B2 |
| 7115250 | Rabinowitz et al. | Oct 2006 | B2 |
| 7131599 | Katase | Nov 2006 | B2 |
| 7169378 | Rabinowitz et al. | Jan 2007 | B2 |
| 7229966 | Quay et al. | Jun 2007 | B2 |
| 7402777 | Ron et al. | Jul 2008 | B2 |
| 7442368 | Rabinowitz et al. | Oct 2008 | B2 |
| 7445768 | Rabinowitz et al. | Nov 2008 | B2 |
| 7449172 | Rabinowitz et al. | Nov 2008 | B2 |
| 7449173 | Rabinowitz et al. | Nov 2008 | B2 |
| 7449174 | Rabinowitz et al. | Nov 2008 | B2 |
| 7449175 | Rabinowitz et al. | Nov 2008 | B2 |
| 7458374 | Hale et al. | Dec 2008 | B2 |
| 7465435 | Rabinowitz et al. | Dec 2008 | B2 |
| 7465436 | Rabinowitz et al. | Dec 2008 | B2 |
| 7465437 | Rabinowitz et al. | Dec 2008 | B2 |
| 7468179 | Rabinowitz et al. | Dec 2008 | B2 |
| 7470421 | Rabinowitz et al. | Dec 2008 | B2 |
| 7485285 | Rabinowitz et al. | Feb 2009 | B2 |
| 7488469 | Rabinowitz et al. | Feb 2009 | B2 |
| 7491047 | Rabinowitz et al. | Feb 2009 | B2 |
| 7498019 | Hale et al. | Mar 2009 | B2 |
| 7507397 | Rabinowitz et al. | Mar 2009 | B2 |
| 7507398 | Rabinowitz et al. | Mar 2009 | B2 |
| 7510702 | Rabinowitz et al. | Mar 2009 | B2 |
| 7524484 | Rabinowitz et al. | Apr 2009 | B2 |
| 7537009 | Hale et al. | May 2009 | B2 |
| 7540286 | Cross et al. | Jun 2009 | B2 |
| 7550133 | Hale et al. | Jun 2009 | B2 |
| 20010020147 | Staniforth et al. | Sep 2001 | A1 |
| 20010037104 | Zhang et al. | Nov 2001 | A1 |
| 20010039262 | Venkataraman | Nov 2001 | A1 |
| 20010042546 | Umeda et al. | Nov 2001 | A1 |
| 20020000225 | Schuler et al. | Jan 2002 | A1 |
| 20020031480 | Peart et al. | Mar 2002 | A1 |
| 20020035945 | Knowlton et al. | Mar 2002 | A1 |
| 20020037437 | Yamamoto | Mar 2002 | A1 |
| 20020037828 | Wilson et al. | Mar 2002 | A1 |
| 20020058009 | Bartus et al. | May 2002 | A1 |
| 20020061281 | Osbakken et al. | May 2002 | A1 |
| 20020078946 | Sprinkel, Jr. et al. | Jun 2002 | A1 |
| 20020078955 | Nichols et al. | Jun 2002 | A1 |
| 20020086852 | Cantor | Jul 2002 | A1 |
| 20020097139 | Gerber et al. | Jul 2002 | A1 |
| 20020112723 | Schuster et al. | Aug 2002 | A1 |
| 20020117175 | Kottayil et al. | Aug 2002 | A1 |
| 20020176841 | Barker et al. | Nov 2002 | A1 |
| 20030004142 | Prior et al. | Jan 2003 | A1 |
| 20030015196 | Hodges et al. | Jan 2003 | A1 |
| 20030032638 | Kim et al. | Feb 2003 | A1 |
| 20030037437 | Das et al. | Feb 2003 | A1 |
| 20030051728 | Lloyd et al. | Mar 2003 | A1 |
| 20030062042 | Wensley et al. | Apr 2003 | A1 |
| 20030070738 | Hamilton | Apr 2003 | A1 |
| 20030106551 | Sprinkel et al. | Jun 2003 | A1 |
| 20030118512 | Shen | Jun 2003 | A1 |
| 20030131843 | Lu | Jul 2003 | A1 |
| 20030138508 | Novack et al. | Jul 2003 | A1 |
| 20040009128 | Rabinowitz et al. | Jan 2004 | A1 |
| 20040016427 | Byron et al. | Jan 2004 | A1 |
| 20040083919 | Hosey et al. | May 2004 | A1 |
| 20040096402 | Hodges et al. | May 2004 | A1 |
| 20040099266 | Cross et al. | May 2004 | A1 |
| 20040101481 | Hale et al. | May 2004 | A1 |
| 20040102434 | Hale et al. | May 2004 | A1 |
| 20040105818 | Every et al. | Jun 2004 | A1 |
| 20040162517 | Furst et al. | Aug 2004 | A1 |
| 20040234699 | Hale et al. | Nov 2004 | A1 |
| 20040234914 | Hale et al. | Nov 2004 | A1 |
| 20040234916 | Hale et al. | Nov 2004 | A1 |
| 20050000711 | Hurlstone et al. | Jan 2005 | A1 |
| 20050016550 | Katase | Jan 2005 | A1 |
| 20050034723 | Bennett et al. | Feb 2005 | A1 |
| 20050037506 | Hale et al. | Feb 2005 | A1 |
| 20050079166 | Damani et al. | Apr 2005 | A1 |
| 20050126562 | Rabinowitz et al. | Jun 2005 | A1 |
| 20050131739 | Rabinowitz et al. | Jun 2005 | A1 |
| 20050268911 | Cross et al. | Dec 2005 | A1 |
| 20060032496 | Hale et al. | Feb 2006 | A1 |
| 20060032501 | Hale et al. | Feb 2006 | A1 |
| 20060120962 | Rabinowitz et al. | Jun 2006 | A1 |
| 20060193788 | Hale et al. | Aug 2006 | A1 |
| 20060247573 | Alexandre et al. | Nov 2006 | A1 |
| 20060257329 | Rabinowitz et al. | Nov 2006 | A1 |
| 20060280692 | Rabinowitz et al. | Dec 2006 | A1 |
| 20070028916 | Hale et al. | Feb 2007 | A1 |
| 20070031340 | Hale et al. | Feb 2007 | A1 |
| 20070122353 | Hale et al. | May 2007 | A1 |
| 20070140982 | Every et al. | Jun 2007 | A1 |
| 20070286816 | Hale et al. | Dec 2007 | A1 |
| 20080110872 | Hale et al. | May 2008 | A1 |
| 20080175796 | Rabinowitz et al. | Jul 2008 | A1 |
| 20080216828 | Wensley | Sep 2008 | A1 |
| 20080299048 | Hale et al. | Dec 2008 | A1 |
| 20080306285 | Hale et al. | Dec 2008 | A1 |
| 20080311176 | Hale et al. | Dec 2008 | A1 |
| 20090062254 | Hale et al. | Mar 2009 | A1 |
| 20090071477 | Hale et al. | Mar 2009 | A1 |
| 20090180968 | Hale et al. | Jul 2009 | A1 |
| Number | Date | Country |
|---|---|---|
| 2152684 | Jan 1996 | CA |
| 436 297 | May 1967 | CH |
| 1082365 | Feb 1994 | CN |
| 1176075 | Mar 1998 | CN |
| 561103 | Jan 1928 | DE |
| 571 289 | Feb 1933 | DE |
| 26 48 308 | Apr 1978 | DE |
| 35 42 447 | Jun 1987 | DE |
| 195 46 341 | Jan 1997 | DE |
| 196 16 627 | Nov 1997 | DE |
| 198 54 007 | May 2000 | DE |
| 198 54 009 | May 2000 | DE |
| 0 039 369 | Nov 1981 | EP |
| 0 244 837 | Nov 1987 | EP |
| 0 264 195 | Apr 1988 | EP |
| 0 274 431 | Jul 1988 | EP |
| 0 277 519 | Aug 1988 | EP |
| 0 279 796 | Aug 1988 | EP |
| 0 358 114 | Mar 1990 | EP |
| 0 363 494 | Apr 1990 | EP |
| 0 430 559 | Jun 1991 | EP |
| 0 430 566 | Jun 1991 | EP |
| 0 492 485 | Jul 1992 | EP |
| 0 532 194 | Mar 1993 | EP |
| 0 606 486 | Jul 1994 | EP |
| 1 325 761 | Oct 1995 | EP |
| 0 734 719 | Feb 1996 | EP |
| 0 780 659 | Jun 1997 | EP |
| 0 816 674 | Jan 1998 | EP |
| 0 936 205 | Aug 1999 | EP |
| 0 967 214 | Dec 1999 | EP |
| 1 065 296 | Jan 2001 | EP |
| 1 079 002 | Feb 2001 | EP |
| 1 080 720 | Mar 2001 | EP |
| 1 177 793 | Feb 2002 | EP |
| 1 222 938 | Jul 2002 | EP |
| 0 808 635 | Jul 2003 | EP |
| 1 345 268 | Sep 2003 | EP |
| 921 852 | May 1947 | FR |
| 1 289 468 | Apr 1962 | FR |
| 2 234 532 | Jan 1975 | FR |
| 2 428 068 | Jan 1980 | FR |
| 2 506 927 | Dec 1982 | FR |
| 502 761 | Jan 1938 | GB |
| 903 866 | Aug 1962 | GB |
| 1 001 901 | Aug 1965 | GB |
| 1 366 041 | Sep 1974 | GB |
| 2 049 651 | Dec 1980 | GB |
| 2 108 390 | May 1983 | GB |
| 2 123 948 | Feb 1984 | GB |
| 200105 | Oct 1988 | HU |
| 219392 | Jun 1993 | HU |
| 57 078968 | May 1982 | JP |
| 58 225001 | Dec 1983 | JP |
| S63-20298 | Jun 1988 | JP |
| WO 8500520 | Feb 1985 | WO |
| WO 8808304 | Nov 1988 | WO |
| WO 9007333 | Jul 1990 | WO |
| WO 9107947 | Jun 1991 | WO |
| WO 9205781 | Apr 1992 | WO |
| WO 9215353 | Sep 1992 | WO |
| WO 9219303 | Nov 1992 | WO |
| WO 9409842 | May 1994 | WO |
| WO 9416717 | Aug 1994 | WO |
| WO 9416757 | Aug 1994 | WO |
| WO 9416759 | Aug 1994 | WO |
| WO 9417369 | Aug 1994 | WO |
| WO 9427576 | Dec 1994 | WO |
| WO 9427653 | Dec 1994 | WO |
| WO 9531182 | Nov 1995 | WO |
| WO 9600069 | Jan 1996 | WO |
| WO 9600070 | Jan 1996 | WO |
| WO 9600071 | Jan 1996 | WO |
| WO 9609846 | Apr 1996 | WO |
| WO 9610663 | Apr 1996 | WO |
| WO 9613290 | May 1996 | WO |
| WO 9631198 | Oct 1996 | WO |
| WO 9717948 | May 1997 | WO |
| WO 9727804 | Aug 1997 | WO |
| WO 9735582 | Oct 1997 | WO |
| WO 9740819 | Nov 1997 | WO |
| WO 9802186 | Jan 1998 | WO |
| WO 9816205 | Apr 1998 | WO |
| WO 9829110 | Jul 1998 | WO |
| WO 9834595 | Aug 1998 | WO |
| WO 9836651 | Aug 1998 | WO |
| WO 9837896 | Sep 1998 | WO |
| WO 9904797 | Feb 1999 | WO |
| WO 9911311 | Mar 1999 | WO |
| WO 9916419 | Apr 1999 | WO |
| WO 9924433 | May 1999 | WO |
| WO 9937347 | Jul 1999 | WO |
| WO 9959710 | Nov 1999 | WO |
| WO 0000176 | Jan 2000 | WO |
| WO 0000244 | Jan 2000 | WO |
| WO 0019991 | Apr 2000 | WO |
| WO 0027359 | May 2000 | WO |
| WO 0027363 | May 2000 | WO |
| WO 0028844 | May 2000 | WO |
| WO 0028979 | May 2000 | WO |
| WO 0029053 | May 2000 | WO |
| WO 0029167 | May 2000 | WO |
| WO 0035417 | Jun 2000 | WO |
| WO 0038618 | Jul 2000 | WO |
| WO 0044350 | Aug 2000 | WO |
| WO 0044730 | Aug 2000 | WO |
| WO 0047203 | Sep 2000 | WO |
| WO 0051491 | Sep 2000 | WO |
| WO 0064940 | Nov 2000 | WO |
| WO 0066084 | Nov 2000 | WO |
| WO 0066106 | Nov 2000 | WO |
| WO 0066206 | Nov 2000 | WO |
| WO 0072827 | Dec 2000 | WO |
| WO 0076673 | Dec 2000 | WO |
| WO 0105459 | Jan 2001 | WO |
| WO 0113957 | Mar 2001 | WO |
| WO 0117568 | Mar 2001 | WO |
| WO 0119528 | Mar 2001 | WO |
| WO 0129011 | Apr 2001 | WO |
| WO 0132144 | May 2001 | WO |
| WO 0141732 | Jun 2001 | WO |
| WO 0143801 | Jun 2001 | WO |
| WO 0166064 | Sep 2001 | WO |
| WO 0169136 | Sep 2001 | WO |
| WO 0180829 | Nov 2001 | WO |
| WO 0195903 | Dec 2001 | WO |
| WO 0200198 | Jan 2002 | WO |
| WO 0224158 | Mar 2002 | WO |
| WO 02051466 | Jul 2002 | WO |
| WO 02051469 | Jul 2002 | WO |
| WO 02056866 | Jul 2002 | WO |
| WO 02060870 | Aug 2002 | WO |
| WO 02083119 | Oct 2002 | WO |
| WO 02094232 | Nov 2002 | WO |
| WO 02094234 | Nov 2002 | WO |
| WO 02094236 | Nov 2002 | WO |
| WO 02094242 | Nov 2002 | WO |
| WO 02098389 | Dec 2002 | WO |
| WO 02098496 | Dec 2002 | WO |
| WO 02102297 | Dec 2002 | WO |
| WO 03021158 | Mar 2003 | WO |
| WO 03024456 | Mar 2003 | WO |
| WO 03037412 | May 2003 | WO |
| WO 03049535 | Jun 2003 | WO |
| WO 03095012 | Nov 2003 | WO |
| WO 04001396 | Dec 2003 | WO |
| WO 2004011396 | Feb 2004 | WO |
| WO 2004054551 | Jul 2004 | WO |
| WO 2004104490 | Dec 2004 | WO |
| WO 2004104491 | Dec 2004 | WO |
| WO 2004104492 | Dec 2004 | WO |
| WO 2004104493 | Dec 2004 | WO |
| WO 2004106268 | Dec 2004 | WO |
| WO 2006022714 | Mar 2006 | WO |
| WO 2006029089 | Mar 2006 | WO |
| Entry |
|---|
| Office Action mailed Jan. 26, 2007 with respect to U.S. Appl. No. 10/057,198. |
| Office Action mailed Jul. 3, 2006 with respect to U.S. Appl. No. 10/057,198. |
| Office Action mailed Sep. 20, 2005 with respect to U.S. Appl. No. 10/057,198. |
| Office Action mailed Dec. 4, 2003 with respect to U.S. Appl. No. 10/057,198. |
| Office Action mailed Jan. 12, 2005 with respect to U.S. Appl. No. 10/057,197. |
| Office Action mailed Jun. 3, 2004 with respect to U.S. Appl. No. 10/057,197. |
| Office Action mailed Jun. 5, 2007 with respect to U.S. Appl. No. 10/057,197. |
| Office Action mailed Sep. 21, 2006 with respect to U.S. Appl. No. 10/057,197. |
| Office Action mailed Dec. 15, 2003 with respect to U.S. Appl. No. 10/057,197. |
| Office Action mailed Feb. 27, 2004 with respect to U.S. Appl. No. 10/146,080. |
| Office Action mailed Mar. 20, 2007 with respect to U.S. Appl. No. 10/146,080. |
| Office Action mailed Jun. 5, 2006 with respect to U.S. Appl. No. 10/146,080. |
| Office Action mailed Aug. 25, 2005 with respect to U.S. Appl. No. 10/146,080. |
| Office Action mailed Dec. 28, 2007 with respect to U.S. Appl. No. 10/146,080. |
| Office Action mailed Feb. 12, 2007 with respect to U.S. Appl. No. 10/146,086. |
| Office Action mailed Oct. 30, 2007 with respect to U.S. Appl. No. 10/146,086. |
| Office Action mailed Dec. 13, 2005 with respect to U.S. Appl. No. 10/146,086. |
| Office Action mailed Feb. 16, 2007 with respect to U.S. Appl. No. 10/146,088. |
| Office Action mailed Sep. 28, 2007 with respect to U.S. Appl. No. 10/146,088. |
| Office Action mailed Nov. 21, 2007 with respect to U.S. Appl. No. 10/146,088. |
| Office Action mailed Mar. 8, 2005 with respect to U.S. Appl. No. 10/718,982. |
| Office Action mailed Jan. 22, 2007 with respect to U.S. Appl. No. 10/851,429. |
| Office Action mailed May 9, 2006 with respect to U.S. Appl. No. 10/851,429. |
| Office Action mailed Oct. 4, 2007 with respect to U.S. Appl. No. 10/851,429. |
| Office Action mailed Jan. 24, 2007 with respect to U.S. Appl. No. 10/851,883. |
| Office Action mailed May 10, 2006 with respect to U.S. Appl. No. 10/851,883. |
| Office Action mailed Sep. 18, 2007 with respect to U.S. Appl. No. 10/851,883. |
| Office Action mailed Jan. 30, 2007 with respect to U.S. Appl. No. 10/851,432. |
| Office Action mailed May 3, 2006 with respect to U.S. Appl. No. 10/851,432. |
| Office Action mailed Sep. 18, 2007 with respect to U.S. Appl. No. 10/851,432. |
| Office Action mailed Mar. 5, 2007 with respect to U.S. Appl. No. 10/917,735. |
| Office Action mailed Dec. 11, 2007 with respect to U.S. Appl. No. 10/917,735. |
| Al-Awadi et al. (2005) “Kinetics and mechanism of thermal gas-phase elimination of β-substituted carboxylic acids” Tetrahedron, 61:5769-5777. |
| Anderson, M.E. (1982). “Recent Advances in Methodology and Concepts for Characterizing Inhalation Pharmacokinetic Parameters in Animals and Man,” Drug Metabolism Reviews. 13(5):799-826. |
| Anonymous, (Jun. 1998) Guidance for Industry: Stability testing of drug substances and products, U.S. Department of Health and Human Services, FDA, CDER, CBER , pp. 1-110. |
| Bacigalupo et al. (1999) “Time-Resolved Fluoroimmunoassay for Δ9- Tetrahydrocannabinol As Applied to Early Discrimination of Cannabis sativa Plants” Journal of Agricultural and Food Chemistry, 47:2743-2745. |
| Banhart (2000) JOM 22-27. |
| Banhart (2001) Prog. In Mater. Sci. 46:559-632. |
| Bastin, R. J. et al. (2000) “Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities”, Organic Process Research & Development 4:427-435. |
| Bennett, R. L. et al. (1981). “Patient-Controlled Analgesia: A New Concept of Postoperative Pain Relief,” Annual Surg. 195(6):700-705. |
| Benowitz (1994). “Individual Differences in Nicotine Kinetics and Metabolism in Humans,” NIDA Research Monography, 2 pages. |
| Berkó et al. (2002) “In vitro and in vivo study in rats of rectal suppositories containing furosemide.” European Journal of Pharmaceutics and Biopharmaceutics vol. 53:311-315. |
| Bigal, et al. (2002) “Intravenous Chlorpromazine in the Emergency Department Treatment of Migraines: A Randomized Controlled Trial.” The Journal of Emergency Medicine vol. 23, No. 2: 141-148. |
| Blanda et al. (2001) “Intranasal Lidocaine for the Treatment of Migraine Headache: A Randomized Controlled Trial.” Academic Emergency Medicine vol. 8:337-342. |
| Bowden, et al. (1988) “The Effect of Trifluoperazine on Bronchial Responsiveness in Asthma” Clinical and Experimental Pharmacology & Physiology 15: 457-463. |
| BP: Chemicals Products-Barrier Resins (1999). located at <http://www.bp.com/chemicals/products/product.asp> (visited on Aug. 2, 2001), 8 pages. |
| Brand, P. et al. (Jun. 2000). “Total Deposition of Therapeutic Particles During Spontaneous and Controlled Inhalations,” Journal of Pharmaceutical Sciences. 89(6):724-731. |
| Caley, C.F. et al. (1998) “Focus on quetiapine: the fourth atypical antipsycotic” Formulary col. 33 No. 2: 105-119. |
| Campbell, Fiona A. et al. (2001) “Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systemic review,” BMJ, 323 pp. 1-6. |
| Carroll, M.E. et al. (1990), “Cocaine-Base Smoking in Rhesus Monkey: Reinforcing and Physiological Effects,” Psychopharmacology (Berl) 102:443-450. |
| Cavaliere et al. (2002) “Furosemide Protective Effect Against Airway Obstruction.” Website http://www.bentham.org/sample-issues/cdt3-3/cavaliere/cavaliere-ms.htm. |
| Caviness, Verne S. (May 1980) “Cluster Headache: Response to Chlorpromazine” Headache 128-131. |
| Cichewicz, Diana L. et al. (May 1999) “Enhancement of mu opioid antinociception by oral DELTA 9—tetrahydrocannabinol: Dose response analysis and receptor identification” Journal of Pharmacology and Experimental Therapeutics vol. 289 (2): 859-867. |
| Clark, A. and Byron, P. (1986). “Dependence of Pulmonary Absorption Kinetics on Aerosol Particle Size,” Z. Erkrank. 166:13-24. |
| Collins, et al. (2001) “Intravenous Administration of Prochlorperazine by 15-Minute Infusion Versus 2-Minute Bolus Does Not Affect the Incidence of Akathisia: A prospective Randomized, Controlled Trial” Annals of Emergency Medicine 38:5 491-496. |
| Coppola et al. (1995) “Randomized, Placebo-Controlled Evaluation of Prochlorperazine Versus Metoclopramide for Emergency Department Treatment of Migraine Headache” Annals of Emergency Medicine vol. 25 No. 5. |
| Coppola et al. (1995) Abstract: “A Prospective, Double-blind Evaluation of Prochlorperazine vs. Sumatriptan for the Emergency Department Treatment of Migraine Headache.” Annual Meeting Abstracts vol. 2 No. 5: 367-368. |
| Crabbe et al. (1971) “Synthesis of New Heterocyclic Derivatives of Estradiol” Tetrahedron 27:711-725. |
| Dahloef, et al. (1998) “Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies” Cephalagia vol. 18: 594-604. |
| Dallas, C. et al. (1983). “A Small Animal Model for Direct Respiratory and Hemodynamic Measurements in Toxicokinetic Studies of Volatile Chemicals,” Devlopments in the Science and Practice of Toxicology. Hayes, A. W. et al. eds., Elsevier Science Publishers, New York. pp. 419-422. |
| Darquenne, C. et al. (1997). “Aerosol Dispersion in Human Lung: Comparison Between Numerical Simulations and Experiments for Bolus Tests,” American Physiological Society. 966-974. |
| Database Biosis “Online!” Biosciences Information Service, Philadelphia, PA 1979, Knight, V. et al., “Amantadine aerosol in humans”, database accession No. PREV 198069035552 abstract, &Antimicrobial Agents and Chemotherapy 16(5):572-578. |
| Database Biosis “Online!” Biosciences Information Service, Philadelphia, PA 1979, Wilson. S.Z. et al., “Amatadine Aerosol Particle A.erosol Generation and Delivery to Man” Database accession No. PREV198069008137, abstract & Proceedings of the Society for Experimental Biology and Medicine 161(3):350-354. |
| Database WPI, Section CH, Week 198941, Derwent Publications Ltd., London, GB; AN 1989-297792 AP002230849 & JP 01 221313 (Nippon Create 1(K), Sep. 4, 1989, abstract. |
| Davies, C. N. et al. (May 1972). “Breathing of Half-Micron Aerosols,” Journal of Applied Physiology. 32(5):591-600. |
| De Yong et al. (1998) “Radiative Ignition of Pyrotechnics: Effect of Wavelength on Ignition Threshold” Propellants, Explosives, Pyrotechnics 23:328-332. |
| Dershwitz, M., M.D., et al. (Sep. 2000). “Pharmacokinetics and Pharmacodynamics of Inhaled versus Intravenous Morphine in Healthy Volunteers,” Anesthesiology. 93(3): 619-628. |
| Dettmer et al. (2001) “Take home naloxone and the prevention of deaths from opiate overdose: two pilot schemes.” BMJ 322:895-896. |
| Donohue et al. (1995) Abstract: “Prochlorperazine Versus Sumatriptan for Emergency Department Therapy of Migraine Headache” Annals of Emergency Medicine vol. 25 No. 1: 154. |
| Dormans et al. (1996) “Vascular effects of loop diuretics.” Cardiovascular Research 32:988-997. |
| Drotts, et al. (1999) Ann. Emerg. Med. 34: 469-475. |
| Drug Information Handbook, 2nd edition, Lexi-Comp, Inc.: Cleveland, 1994-1995, pp. 554-555. |
| Drugs Approved by the FDA—Drug Name: Nicotrol Inhaler (2000) located at <http://www.centerwatch.com/patient/drugs/dru202.html> (Visited on Aug. 2, 2001), 2 pages. |
| Faris et al. (2002) “Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomized controlled trials.” International Journal of Cardiology vol. 82:149-158. |
| Feynman, R.P. et al. (1964). “Chapter 32: Refractive Index of Dense Materials” The Feyman Lectures on Physics: Mainly Electromagnetism and Matter. Addison-Wesley: Publishing Company, Inc., Reading, Massachusetts: pp. 32-1-32-13. |
| Finlay, W. H. (2001). “The Mechanics of Inhaled Pharmaceutical Aerosols”, Academic Press: San Diego Formula 2.39. pp. 3-14 (Table of Contents). pp. v-viii. |
| Galeotti Nicoletta et al. (2002). “Indomethacin caffeine and prochlorperazine alone and combined revert hyperalgesia in in vivo models of migraine”, Pharmacological research, vol. 46. No. 3: 245-250. |
| Ginder et al. (2000) “A Prospective Study of I.V. Magnesium and I.V. Prochlorperazine in the Treatment of Headaches” The Journal of Emergency Medicine: vol. 18 No. 3: 311-315. |
| Gleeson, et al. (1982) “Chlorpromazine Hyperalgesia Antagonizes Clonidine Analgesia, but Enhances Morphine Analgesia in Rats Tested in a Hot-Water Tail-Flick Paradigm” Psychopharmacology vol. 78: 141-146. |
| Gonda, I. (1991). “Particle Deposition in the Human Respiratory Tract,” Chapter 176, The Lung: Scientific Foundations. Crystal R.G.and West, J.B. (eds.), Raven Publishers, New York. pp. 2289-2294. |
| Goodall et al. (Sep. 1, 2002) Journal of Aerosol Medicine 15(3):351-357 doi:10.1089/089426802760292717. |
| Gottlieb, S.S. “Renal Effects of Adenosine A1-Receptor Antagonists in Congestive Heart Failure,” Drugs, 2001, 61(10), pp. 1387-1393 (abstract only). |
| Hagenbach, Charles “Prochlorperazine in the Prophylaxis of Migraine” General Practioners' Forum pp. 503-506. |
| Hamon, et al. (1987) “Opioid Receptors and Neuropeptides in the CNS in Rats Treated Chronically with Amoxapine and Amitriptyline” Neuropharmacology vol. 26 No. 6: 531-539. |
| Hansh et al. (1990) Comprehensive medicinal chemistry 5:251-278, Pharmacogenetics. |
| Hatsukami D., et al. (May 1990) “A Method for Delivery of Precise Doses of Smoked Cocaine-Base to Human.” Pharmacology Biochemistry & Behavior. 36(1):1-7. |
| Kreith, Frank et al. “Boundary-Layer Fundamentals” Principles of Heat Transfer. Section 4.3: p. 236-242. |
| Nielsen et al. (2000) “Intranasal Administration of Different Liquid Formulation of Bumetanide to Rabbits” International Journal of Pharmaceutics 204:35-41. |
| Panipol Conductive Inks website (www.panipol.com). |
| Pankow, J. F. et al. (1997). “Conversion of Nicotine in Tobacco Smoke to Its Volatile and Available Free-Base Form through the Action of Gaseous Ammonia,” Environ. Sci. Technol. 31:2428-2433. |
| Perfetti (1983) “Structural study of nicotine salts” Beitraege zur Tabakforschung Internatioal 12(2):43-54. |
| Perfetti (2000) “The transfer of nicotine from nicotine salts to mainstream smoke” Beitraege zur Tabakforschung Internatioal 19(3):141-158. |
| Polosa et al. (1995) “Inhaled Loop Diuretics and Basal Airway Responsiveness in Man: Evidence of a Role for Cyclo-oygenase Products.” Eur. Respir. J 8(4):593-599. |
| Roux, Gillard M. “Laser Diode Ignition of the Combustion of Pyrotechnic Mixtures. Experimental study of the ignition of Zr/KClO4 and Zr/PbCrO4”. |
| Rozen et al. (2001) “Olanzapinea as an Abortive Agent for Cluster Headache.” Headache vol. 41:813-816. |
| Shimoyama et al. (2002) “Nebulized Furosemide as a Novel Treatment for Dyspnea in Terminal Cancer Patients.” Journal of Pain and Symptom Management vol. 23 No. 1: 73:76. |
| Shrestha et al. (1996) “Ketorolac vs Chlorpormazine in the Treatment of Acute Migraine Without Aura.” Arch. Intern. Med. vol. 156:1725-1728. |
| Wilknson M. (1985). “Migraine-treatment of acute attack”, Scottish Medical Journal vol. 30 No. 4: 258-262. |
| U.S. Appl. No. 11/687,466, filed Mar. 16, 2007, Zaffaroni et al. |
| U.S. Appl. No. 12/211,247, filed Sep. 16. 2008, Sharma et al. |
| U.S. Appl. No. 12/211,554, filed Sep. 16, 2008, Sharma et al. |
| U.S. Appl. No. 12/211,628, filed Sep. 16, 2008, Lei et al. |
| U.S. Appl. No. 12/413,339, filed Mar. 27, 2009, Rabinowitz et al. |
| U.S. Appl. No. 12/471,070, filed May 22, 2009, Hale et al. |
| U.S. Appl. No. 12/474,680, filed May 29, 2009, Cross et al. |
| U.S. Appl. No. 12/490,102, filed Jun. 23, 2009, Hale et al. |
| Number | Date | Country | |
|---|---|---|---|
| 20090301363 A1 | Dec 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| 60472697 | May 2003 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10850895 | May 2004 | US |
| Child | 12485704 | US | |
| Parent | 10851429 | May 2004 | US |
| Child | 10850895 | US | |
| Parent | 10851883 | May 2004 | US |
| Child | 10851429 | US | |
| Parent | 10851432 | May 2004 | US |
| Child | 10851883 | US |
